

# UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY

England & Wales · Charity number 1148145

## Details

---

Other names	UKI NETS
Status	Registered
Legal form	Charitable company
Company number	<a href="#">06672185</a>
Registered	2012-07-16
Register	<a href="#">View on the Charity Commission register</a>

## Contact

---

Address	Starling House Unit 1600 Bradley Stoke Bristol BS34 8YU
Phone	01454 642277
Email	<a href="mailto:ukinets@endocrinology.org">ukinets@endocrinology.org</a>
Website	<a href="http://www.ukinets.org">www.ukinets.org</a>

## Activities

---

**Objects:** THE SOCIETY'S OBJECTS ARE TO PROMOTE FOR THE PUBLIC BENEFIT RESEARCH, EDUCATION AND IMPROVED QUALITY OF CLINICAL PRACTICE IN NEUROENDOCRINE TUMOURS BY THE ORGANISATION OF CONFERENCES, TRAINING COURSES AND PUBLICATIONS, BY RAISING PUBLIC AWARENESS, LIAISON WITH NATIONAL AND INTERNATIONAL LEGISLATORS, AND BY ANY OTHER APPROPRIATE MEANS. THE SOCIETY AIMS TO IMPROVE THE DIAGNOSIS, THERAPY AND SURVIVORSHIP OF PATIENTS WITH NEUROENDOCRINE TUMOURS WITHIN A NATIONAL MULTIDISCIPLINARY AND SCIENTIFIC CONTEXT.

**Activities:** To promote professional and public awareness of NET throughout the UK and Ireland with the aim of optimising patient care and outcomes. This will be achieved through research, education, communications and patient and professional advocacy, working with other professional bodies, charities, patient groups and governments.

## Classification

---

- **How:** Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** Education/training, The Advancement Of Health Or Saving Of Lives
- **Who:** Children/young People, Other Charities Or Voluntary Bodies, Other Defined Groups, The General Public/mankind

## Geography

---

- Ireland
- Northern Ireland
- Scotland
- Throughout England And Wales

## Finances

---

Period end	Income	Expenditure	Assets	Employees
2025-08-31	£127,960	£121,502	-	-
2024-08-31	£137,480	£121,922	-	-
2023-08-31	£57,634	£70,089	-	-
2022-08-31	£97,892	£86,097	-	-
2021-08-31	£95,166	£85,800	-	-
2020-08-31	£134,527	£97,759	-	-

## Trustees

---

Name	Role	Appointed
David Mark Pritchard		2021-12-06
Dr Alia Munir		2024-12-02
Dr Rajaventhana Srirajaskanthan		2023-12-04
Dr Tahir Hussain Shah		2018-06-01

**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY**

England & Wales - Charity number 1148145

---

# Accounts

---

**UK And Ireland Neuroendocrine Tumour Society Limited**

**Charity No. 1148145**

**Company No. 06672185**

**Trustees' Report and Unaudited Accounts**

**31 August 2025**

Registered Address:

Starling House  
Unit 1600 Bristol Parkway North  
Bradley Stoke  
Bristol  
BS34 8YU

**UK And Ireland Neuroendocrine Tumour Society Limited**  
**Contents**

	Pages
Trustees' Annual Report	2 to 6
Independent Examiner's Report	7
Statement of Financial Activities	8 to 9
Balance Sheet	10
Notes to the Accounts	11 to 15
Detailed Statement of Financial Activities	16 to 17

The trustees, who are also directors of the charity for the purposes of the Companies Act 2006, present their report and unaudited financial statements of the charity for the year ending 31 August 2025.

### **Trustees**

The trustees, who are also the directors for the purposes of company law, and who served during the year and up to the date of signature of the unaudited financial statements were:

Prof T H Shah

Prof C Thirlwell – resigned 2 December 2024

Prof M Pritchard

Prof R Srirajaskanthan

Dr A Munir – appointed 2 December 2024

None of the directors has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £1 in the event of winding up.

### **Governing document**

The UK and Ireland Neuroendocrine Tumour Society Limited (UKI NETS) is constituted by its Memorandum & Articles of Association, adopted by the membership on 7 December 2015, and is a registered charity. UKI NETS became a company limited by guarantee on 13 August 2008 and was subsequently registered as a charity on 16 July 2012.

### **Organisational structure**

The Society has four main categories of membership as follows: Clinician; Scientist; Nurse and Allied Health Professional Members. Each of these categories is broken down into career stages. All members are given the option of membership with or without inclusive ENETS membership. Membership of the charity is open to any medical professionals or scientists interested in promoting the objects.

The Society is governed by four Executive Officers, who are the directors and trustees (Chair, Past Chair or Chair-elect, Treasurer and Secretary), supported by a wider Executive Committee, which includes chairs of the sub committees. All Executive Officers and Executive Committee members are elected by member ballot.

### **Risk management**

The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error.

## Objectives and activities

The charity's objects are to promote for the public benefit research, education and clinical practice in neuroendocrine tumours by the organisation of conferences, training courses and publications, by raising public awareness, liaison with national and international legislators, and by any other appropriate means. The Society aims to improve the diagnosis and therapy of patients with neuroendocrine tumours within a national multidisciplinary and scientific context.

In furtherance of its objects, the Society shall have the following powers:

1. To arrange and provide for the holding of meetings, lectures and seminars.
2. To procure to be written and print, publish, issue and circulate gratuitously or otherwise such papers, periodicals, pamphlets or other documents.
3. To raise funds and to invite and receive contributions from any person or persons whatsoever by way of subscriptions and otherwise provided that the Society shall not undertake any permanent trading activities in raising funds for its primary charitable objectives.
4. To co-operate, associate or affiliate with any other charitable institutions.
5. To do all such other lawful things as are necessary for the attainment of the above objectives.

The summary of main activities in relation to the charity objectives are as follows:

- Annual Scientific Meeting
- Provision of travel grants
- Provision of meeting awards
- Allocation of research grants provided by Neuroendocrine Cancer UK
- Provision of educational activities (webinars and NET for Newcomers training day)
- Guideline development
- Public/healthcare professional engagement in association with Neuroendocrine Cancer UK
- Promotion of research

All trustees have had regard to the Charity Commission's guidance on public benefit when planning for the Society's activities.

## Achievements and performance

### UKI NETS 22nd Annual Conference: Cardiff

The 22<sup>nd</sup> Annual Conference of the Society was held at Mercure Holland House Hotel in Cardiff on Monday 2 December 2024.

The programme contained sessions focused on: Multi-Disciplinary Challenges in Clinical Practice; a clinical trials overview; immunotherapy in patients with high grade NENs; recent developments in PRRT; MEN Syndromes and Challenges; a NET translational medicine session and a NET nurses' session. Posters and oral communications were presented. The conference ended with a Prize Giving session and a lifetime achievement award was presented during the day. Satellite symposia were also held by sponsors.

## **Provision of travel grants**

Five travel grants were awarded to the presenters of the best scoring abstracts for the conference (excluding physicians in post more than 5 years). Four were awarded free membership for a year; one current member was awarded £100.

## **Provision of meeting awards**

Prizes were awarded to the top three best scoring clinical and scientific posters and the best oral communication at the 22<sup>nd</sup> Annual Conference.

## **Provision of Research grants**

Neuroendocrine Cancer UK (NCUK), in association with UKINETS, awarded two pump priming grants of £25k each to provide pump-priming funds to support research projects designed to improve outcomes for patients with neuroendocrine cancer.

## **Public Engagement**

UKI NETS members have been involved with and supporting the Neuroendocrine Cancer UK awareness campaign for healthcare professionals, 'Spotlight on Neuroendocrine Cancer', developing NET overviews for those who see NET patients but are not experts.

## **Educational activities**

NETs for Newcomers:

On 9<sup>th</sup> May 2025 UKINETS presented the eighth annual one day course for doctors and HCPs of all specialties who wished to learn more about Neuroendocrine Tumours. It was held face to face in Manchester. The course was delivered by an expert multidisciplinary faculty and included a 'mock MDT' practice in small groups. Approximately 34 HCPs attended and feedback was very positive. 6 CPD points were awarded to attendees.

Webinars:

UKINETS continued to deliver its series of educational webinars, led by the Education and Training Committee. Webinars were delivered on NET oncology and theragnostics. The webinars are free to attend for both members and non-members of UKINETS.

## **Guideline development**

The UKINETS Clinical Practice Committee continues to create clinical guideline documents for its Bitesize Guidance library, available on the UKINETS website. As well as the creation of new guidance, existing guidance was reviewed and updated.

## **Dietitians' Working Group**

The AHP/Dietitian representative on the Executive Committee also chairs the UKINETS Dietitians' Working Group. The group delivered a teaching session for dietitians and nurses, compiled data from UK Centre of Excellence NET centres on dietitian support (or lack of) for the NET MDT and began planning a NET nutrition study day for early 2026.

## **Sponsor Support**

There was financial support to the Society in the form of sponsorship from pharmaceutical and technology companies with products relevant to NETs. The majority of the funding was provided as sponsorship for the National Conference and NETs for Newcomers Training Day.

## **Website**

The charity's website provides an important tool to inform members and the general public about the activities of the Society, as well as updates in NET research. <http://www.ukinets.org>.

## **Communications**

UKI NETS communicates with its members by means of an e-newsletter delivering news from the Society and the wider field. In addition, the charity highlights on its website news and research relating to the field of neuroendocrine tumours. The charity also has its own X account @UKINETS. The Society is in the process of investigating the use of other social networks.

## **Clinical Trials and Research Development**

UKINETS includes a summary of recent clinical trials related to NETs on its website and at its annual scientific conference.

UKINETS has continued to manage a project to set up a national database for NETs to facilitate valuable future research.

## **Link with the European Neuroendocrine Tumour Society (ENETS)**

UKI NETS continues to provide optional inclusive membership to its members to its European partner Society, ENETS. Through membership of ENETS, UKI NETS members have access to *Journal of Neuroendocrinology* and a reduced rate for the ENETS annual conference. A member of UKINETS sits on the Executive Committee of ENETS.

## **Financial review**

### **Principal funding sources**

Income to the Society is mainly generated through industry support, the annual conference and membership subscriptions. Personal donations/legacies are received on an ad hoc basis.

### **Reserves policy**

The reserve policy takes into consideration the major risks that could face the Society.

It is the policy of the Society to maintain unrestricted funds, which are the free reserves of the charity. The reserves are held at a level that ensures the financial viability of the Society. That level is currently deemed to be one that equates to a minimum of two years' expenditure. The officers of the Society will be reviewing this policy to ensure it still fit for purpose. The balance sheet indicates that there are £168,917 unrestricted funds as at 31 August 2025. This provides sufficient funds to cover management, administration and support costs.

## Plans for future periods

The UKI NETS 23<sup>rd</sup> Annual Conference is scheduled to be held in London in December 2025, with abstracts submitted and posters and oral communications presented as usual.

Other plans for the coming year include:

- Holding a NET Nutrition Study Day in January 2026
- Awarding 3 x Pump Priming Grants and 2 x Practice Changing grants on behalf of NCUK in February 2026
- Holding a further NETs for Newcomers training event in Sheffield in June 2026
- Further developing the library of bite size clinical guidance for the website
- Continuing the delivery of a programme of free educational webinars on varied topics relating to NETs – to improve education and awareness for HCPs, possibly collaborating with partners to deliver more
- Continuing to plan and deliver a national NET database for research purposes
- Collaborating with NCUK to manage the Neuroendocrine Cancer Priority Setting Partnership with the James Lind Alliance
- Endorsement of 'Bronchopulmonary Carcinoids unveiled' (a workshop delivered by the Christie) in January 2026
- Providing feedback on external clinical guidelines where appropriate
- Continuing to secure funding from corporate donors
- Continuing to develop communications with members

The Trustees Report was approved by the Board of Trustees and signed on its behalf by:



Prof R Srirajaskanthan

Trustee

Dated: 29/2/26

Registered Address:  
Starling House  
1600 Bristol Parkway North  
Bristol  
BS34 8YU

**UK And Ireland Neuroendocrine Tumour Society Limited**  
**Independent Examiners Report**

**Independent Examiner's Report to the trustees of UK And Ireland Neuroendocrine Tumour Society Limited**

I report to the charity trustees on my examination of the financial statements of UK And Ireland Neuroendocrine Tumour Society Limited for the year ended 31 August 2025.

**Responsibilities and basis of report**

As the charity's trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 ('the 2006 Act).


Having satisfied myself that the financial statements of the Charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's financial statements as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

**Independent examiner's statement**

I have completed my examination. I can confirm that no material matters have come to my attention in connection with the examination giving me cause to believe:

- accounting records were not kept in accordance with section 386 of the 2006 Act ; or
- the financial statements do not accord with those records; or
- the financial statements do not comply with the accounting requirements under section 396 of the 2006 Act other than any requirement that the financial statements give a 'true and fair' view which is not a matter considered as part of an independent examination; or
- the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Andy Hopkins  
BVSC  
Latham House  
33-34 Paradise Street  
Birmingham

B1 2AJ  
19 January 2026

UK And Ireland Neuroendocrine Tumour Society Limited

Statement of Financial Activities

for the year ended 31 August 2025

	Notes	Unrestricted funds 2025 £	Restricted funds 2025 £	Total funds 2025 £	Total funds 2024 £
<b>Income and endowments from:</b>					
Donations and legacies	4	23,526	-	23,526	23,252
Charitable activities	5	104,234	-	104,234	114,228
Other	6	200	-	200	-
<b>Total</b>		<b>127,960</b>	<b>-</b>	<b>127,960</b>	<b>137,480</b>
<b>Expenditure on:</b>					
Charitable activities	7	56,149	5,068	61,217	70,435
Other	8	60,285	-	60,285	51,486
<b>Total</b>		<b>116,434</b>	<b>5,068</b>	<b>121,502</b>	<b>121,921</b>
Net gains on investments		-	-	-	-
<b>Net income</b>	9	<b>11,526</b>	<b>(5,068)</b>	<b>6,458</b>	<b>15,559</b>
Transfers between funds		396	(396)	-	-
<b>Net income before other gains/(losses)</b>		<b>11,922</b>	<b>(5,464)</b>	<b>6,458</b>	<b>15,559</b>
<b>Other gains and losses</b>					
<b>Net movement in funds</b>		<b>11,922</b>	<b>(5,464)</b>	<b>6,458</b>	<b>15,559</b>
<b>Reconciliation of funds:</b>					
Total funds brought forward		156,995	5,464	162,459	146,900
<b>Total funds carried forward</b>		<b>168,917</b>	<b>-</b>	<b>168,917</b>	<b>162,459</b>

UK And Ireland Neuroendocrine Tumour Society Limited  
Summary Income and Expenditure Account  
for the year ended 31 August 2025

	2025 £	2024 £
Income	127,960	137,480
<b>Gross income for the year</b>	<u>127,960</u>	<u>137,480</u>
Expenditure	121,502	121,922
<b>Total expenditure for the year</b>	<u>121,502</u>	<u>121,922</u>
Net income before tax for the year	6,458	15,558
<b>Net income for the year</b>	<u><u>6,458</u></u>	<u><u>15,558</u></u>

UK And Ireland Neuroendocrine Tumour Society Limited

Balance Sheet

at 31 August 2025

Company No. 06672185	Notes	2025 £	2024 £
<b>Current assets</b>			
Debtors	11	30,447	31,254
Cash at bank and in hand		144,492	137,060
		<u>174,939</u>	<u>168,314</u>
<b>Creditors: Amount falling due within one year</b>	12	(6,022)	(5,855)
<b>Net current assets</b>		168,917	162,459
<b>Total assets less current liabilities</b>		168,917	162,459
<b>Net assets excluding pension asset or liability</b>		168,917	162,459
<b>Total net assets</b>		<u>168,917</u>	<u>162,459</u>
<b>The funds of the charity</b>			
<b>Restricted funds</b>			
Restricted income funds	13	-	5,464
		<u>-</u>	<u>5,464</u>
<b>Unrestricted funds</b>			
General funds	13	168,917	156,995
		<u>168,917</u>	<u>156,995</u>
<b>Reserves</b>	13		
<b>Total funds</b>		<u>168,917</u>	<u>162,459</u>

These accounts have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.


For the year ended 31 August 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

Approved by the board on 13 February 2026

And signed on its behalf by:



R. Srirajaskanthan

Trustee

Date: 24/2/2026

## 1 Accounting policies

### Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

### Change in basis of accounting or to previous accounts

There has been no change to the accounting policies (valuation rules and method of accounting) since last year and no changes have been made to accounts for previous years.

### Fund accounting

Unrestricted funds	These are available for use at the discretion of the trustees in furtherance of the general objects of the charity.
Designated funds	These are unrestricted funds earmarked by the trustees for particular purposes.
Revaluation funds	These are unrestricted funds which include a revaluation reserve representing the restatement of investment assets at their market values.
Restricted funds	These are available for use subject to restrictions imposed by the donor or through terms of an appeal.

### Income

Recognition of income	Income is included in the Statement of Financial Activities (SoFA) when the charity becomes entitled to, and virtually certain to receive, the income and the amount of the income can be measured with sufficient reliability.
Income with related expenditure	Where income has related expenditure the income and related expenditure is reported gross in the SoFA.
Donations and legacies	Voluntary income received by way of grants, donations and gifts is included in the the SoFA when receivable and only when the Charity has unconditional entitlement to the income.
Tax reclaims on donations and gifts	Income from tax reclaims is included in the SoFA at the same time as the gift/donation to which it relates.
Donated services and facilities	These are only included in income (with an equivalent amount in expenditure) where the benefit to the Charity is reasonably quantifiable, measurable and material.
Volunteer help	The value of any volunteer help received is not included in the accounts.
Investment income	This is included in the accounts when receivable.
Gains/(losses) on revaluation of fixed assets	This includes any gain or loss resulting from revaluing investments to market value at the end of the year.
Gains/(losses) on investment assets	This includes any gain or loss on the sale of investments.

Notes to the Accounts

**Expenditure**

Recognition of expenditure	Expenditure is recognised on an accruals basis. Expenditure includes any VAT which cannot be fully recovered, and is reported as part of the expenditure to which it relates.
Expenditure on raising funds	These comprise the costs associated with attracting voluntary income, fundraising trading costs and investment management costs.
Expenditure on charitable activities	These comprise the costs incurred by the Charity in the delivery of its activities and services in the furtherance of its objects, including the making of grants and governance costs.
Grants payable	All grant expenditure is accounted for on an actual paid basis plus an accrual for grants that have been approved by the trustees at the end of the year but not yet paid.
Governance costs	These include those costs associated with meeting the constitutional and statutory requirements of the Charity, including any audit/independent examination fees, costs linked to the strategic management of the Charity, together with a share of other administration costs.
Other expenditure	These are support costs not allocated to a particular activity.

**Taxation**

The charity is exempt from corporation tax on its charitable activities.

**Trade and other debtors**

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

**2 Company status**

The company is a private company limited by guarantee and consequently does not have share capital.

UK And Ireland Neuroendocrine Tumour Society Limited  
Notes to the Accounts

3 Statement of Financial Activities - prior year

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total funds 2024 £
<b>Income and endowments from:</b>			
Donations and legacies	23,252	-	23,252
Charitable activities	114,228	-	114,228
<b>Total</b>	<u>137,480</u>	<u>-</u>	<u>137,480</u>
<b>Expenditure on:</b>			
Charitable activities	121,922	-	121,922
<b>Total</b>	<u>121,922</u>	<u>-</u>	<u>121,922</u>
<b>Net income</b>	<u>15,558</u>	<u>-</u>	<u>15,558</u>
<b>Net income before other gains/(losses)</b>	15,558	-	15,558
<b>Other gains and losses:</b>			
<b>Net movement in funds</b>	<u>15,558</u>	<u>-</u>	<u>15,558</u>
<b>Reconciliation of funds:</b>			
Total funds brought forward	141,436	5,464	146,900
<b>Total funds carried forward</b>	<u><u>156,994</u></u>	<u><u>5,464</u></u>	<u><u>162,458</u></u>

4 Income from donations and legacies

	Unrestricted £	Total 2025 £	Total 2024 £
Donations and gifts	2,064	2,064	4,350
Membership Fees	21,462	21,462	18,902
	<u>23,526</u>	<u>23,526</u>	<u>23,252</u>

5 Income from charitable activities

	Unrestricted £	Total 2025 £	Total 2024 £
Sponsorship	104,234	104,234	114,228
	<u>104,234</u>	<u>104,234</u>	<u>114,228</u>

6 Other income

	Unrestricted £	Total 2025 £	Total 2024 £
	200	200	-
	<u>200</u>	<u>200</u>	<u>-</u>

UK And Ireland Neuroendocrine Tumour Society Limited  
Notes to the Accounts

7 Expenditure on charitable activities

	Unrestricted	Restricted	Total	Total
	2025	2025	2025	2024
	£	£	£	£
<i>Expenditure on charitable activities</i>				
Conferences and newsletters	56,149	-	56,149	70,308
Application development costs	-	5,068	5,068	-
<i>Governance costs</i>				
	-	-	-	127
	<u>56,149</u>	<u>5,068</u>	<u>61,217</u>	<u>70,435</u>

8 Other expenditure

	Unrestricted	Total	Total
	2025	2025	2024
	£	£	£
Other operating costs	44,623	44,623	37,238
Management and Accountancy	15,662	15,662	14,248
	<u>60,285</u>	<u>60,285</u>	<u>51,486</u>

9 Net income before transfers

	2025	2024
	£	£
This is stated after charging:		
Independent Examiner's fee	1,440	1,440

10 Staff costs

No employee received emoluments in excess of £60,000.

11 Debtors

	2025	2024
	£	£
Other debtors	5,447	-
Prepayments and accrued income	25,000	31,254
	<u>30,447</u>	<u>31,254</u>

12 Creditors:

amounts falling due within one year

	2025	2024
	£	£
Accruals	6,022	5,855
	<u>6,022</u>	<u>5,855</u>

Notes to the Accounts

13 Movement in funds

	At 1 September 2024	Incoming resources (including other gains/losses) £	Resources expended £	Gross transfers £	At 31 August 2025 £
<b>Restricted funds:</b>					
<b>Restricted income funds:</b>					
TransNet	5,464	-	(5,068)	(396)	-
<i>Total</i>	<u>5,464</u>	<u>-</u>	<u>(5,068)</u>	<u>(396)</u>	<u>-</u>
<b>Unrestricted funds:</b>					
<b>General funds</b>	156,995	127,960	(116,434)	396	168,917
<b>Total funds</b>	<u>162,459</u>	<u>127,960</u>	<u>(121,502)</u>	<u>-</u>	<u>168,917</u>

Purposes and restrictions in relation to the funds:

Restricted funds:

TransNet

14 Analysis of net assets between funds

	Unrestricted funds £	Restricted funds £	Total £
Net current assets	163,470	5,447	168,917
	<u>163,470</u>	<u>5,447</u>	<u>168,917</u>

15 Reconciliation of net debt

	At 1 September 2024 £	Cash flows £	At 31 August 2025 £
Cash and cash equivalents	137,060	7,432	144,492
	<u>137,060</u>	<u>7,432</u>	<u>144,492</u>
Net debt	<u>137,060</u>	<u>7,432</u>	<u>144,492</u>

16 Related party disclosures

**Controlling party**

The company is limited by guarantee and has no share capital; thus no single party controls the company.

UK And Ireland Neuroendocrine Tumour Society Limited

Detailed Statement of Financial Activities

for the year ended 31 August 2025

	Unrestricted funds 2025 £	Restricted funds 2025 £	Total funds 2025 £	Total funds 2024 £
<b>Income and endowments from:</b>				
Donations and legacies				
Donations and gifts	2,064	-	2,064	4,350
Membership Fees	21,462	-	21,462	18,902
	<u>23,526</u>	<u>-</u>	<u>23,526</u>	<u>23,252</u>
Charitable activities				
Sponsorship	104,234	-	104,234	114,228
	<u>104,234</u>	<u>-</u>	<u>104,234</u>	<u>114,228</u>
Other				
	200	-	200	-
	<u>200</u>	<u>-</u>	<u>200</u>	<u>-</u>
<b>Total income and endowments</b>	<b>127,960</b>	<b>-</b>	<b>127,960</b>	<b>137,480</b>
<b>Expenditure on:</b>				
Charitable activities				
Conferences and newsletters	56,149	-	56,149	70,308
Application development costs	-	5,068	5,068	-
	<u>56,149</u>	<u>5,068</u>	<u>61,217</u>	<u>70,308</u>
Governance costs				
	-	-	-	127
	<u>-</u>	<u>-</u>	<u>-</u>	<u>127</u>
<b>Total of expenditure on charitable activities</b>	<b>56,149</b>	<b>5,068</b>	<b>61,217</b>	<b>70,435</b>
General administrative costs, including depreciation and amortisation				
Software, IT support and related costs	3,136	-	3,136	5,095
Subscriptions	9,770	-	9,770	5,643
Sundry expenses	31,717	-	31,717	26,500
	<u>44,623</u>	<u>-</u>	<u>44,623</u>	<u>37,238</u>
Legal and professional costs				
Audit/Independent examination fees	1,440	-	1,440	1,160
Management charges	14,222	-	14,222	13,088
	<u>15,662</u>	<u>-</u>	<u>15,662</u>	<u>14,248</u>
<b>Total of expenditure of other costs</b>	<b>60,285</b>	<b>-</b>	<b>60,285</b>	<b>51,486</b>
<b>Total expenditure</b>	<b>116,434</b>	<b>5,068</b>	<b>121,502</b>	<b>121,921</b>
Net gains on investments	-	-	-	-

**UK And Ireland Neuroendocrine Tumour Society Limited**  
**Detailed Statement of Financial Activities**

<b>Net income</b>	11,526	(5,068)	6,458	15,559
Transfers between funds	396	(396)	-	-
<b>Net income before other gains/(losses)</b>	11,922	(5,464)	6,458	15,559
Other Gains	-	-	-	-
<b>Net movement in funds</b>	11,922	(5,464)	6,458	15,559
<b>Reconciliation of funds:</b>				
Total funds brought forward	156,995	5,464	162,459	146,900
<b>Total funds carried forward</b>	<b>168,917</b>	<b>-</b>	<b>168,917</b>	<b>162,459</b>

**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY**

England & Wales - Charity number 1148145

---

# Accounts

---

**Charity Registration Number: 1148145**

**Company Registration Number: 06672185 (England and Wales)**

**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**  
**UNAUDITED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 AUGUST 2024**

## CONTENTS

	<b>Page</b>
Legal and administrative information	2
Trustees' Report	3 to 7
Independent examiners report	8
Statement of financial activities	9
Balance sheet	10
Notes to the financial statements	11 to 16

## **LEGAL AND ADMINSTRATIVE INFORMATION**

### **Trustees**

Dr T H Shah

Prof C Thirlwell - resigned 2 December 2024

Prof M Pritchard

Prof R Srirajaskanthan – appointed 4 Dec 2023

Dr A Munir – appointed 2 December 2024

### **Registered Office**

Starling House

1600 Bristol Parkway North

Newbrick Road

Bristol

England

BS34 8YU

**Charity number:** 1148145

**Company number:** 06672185 (registered in England and Wales)

### **Independent Examiner**

Andy Hopkins

BVSC Accountancy Services

Latham House

33-34 Paradise Street

Birmingham

B1 2AJ

## **TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2024**

The trustees, who are also directors of the charity for the purposes of the Companies Act 2006, present their report and unaudited financial statements of the charity for the year ending 31 August 2024.

### **Trustees**

The trustees, who are also the directors for the purposes of company law, and who served during the year and up to the date of signature of the unaudited financial statements were:

Dr T H Shah

Prof C Thirlwell – resigned 2 December 2024

Prof M Pritchard

Prof R Srirajaskanthan – appointed 4 Dec 2023

Dr A Munir – appointed 2 December 2024

None of the directors has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £1 in the event of winding up.

### **Governing document**

The UK and Ireland Neuroendocrine Tumour Society Limited (UKI NETS) is constituted by its Memorandum & Articles of Association, adopted by the membership on 7 December 2015, and is a registered charity. UKI NETS became a company limited by guarantee on 13 August 2008 and was subsequently registered as a charity on 16 July 2012.

### **Organisational structure**

The Society has four main categories of membership as follows: Clinician; Scientist; Nurse and Allied Health Professional Members. Each of these categories is broken down into career stages. All members are given the option of membership with or without inclusive ENETS membership. Membership of the charity is open to any medical professionals or scientists interested in promoting the objects.

The Society is governed by four Executive Officers, who are the directors and trustees (Chair, Past Chair or Chair-elect, Treasurer and Secretary), supported by a wider Executive Committee, which includes chairs of the sub committees. The role of Chair-elect was introduced in 2023 to ensure continuity of knowledge and experience. The Articles of Association were updated accordingly by Special Resolution at the AGM on 4 December 2023.

### **Risk management**

The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error.

## **TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2024**

### **Objectives and activities**

The charity's objects are to promote for the public benefit research, education and clinical practice in neuroendocrine tumours by the organisation of conferences, training courses and publications, by raising public awareness, liaison with national and international legislators, and by any other appropriate means. The Society aims to improve the diagnosis and therapy of patients with neuroendocrine tumours within a national multidisciplinary and scientific context.

In furtherance of its objects, the Society shall have the following powers:

1. To arrange and provide for the holding of meetings, lectures and seminars.
2. To procure to be written and print, publish, issue and circulate gratuitously or otherwise such papers, periodicals, pamphlets or other documents.
3. To raise funds and to invite and receive contributions from any person or persons whatsoever by way of subscriptions and otherwise provided that the Society shall not undertake any permanent trading activities in raising funds for its primary charitable objectives.
4. To co-operate, associate or affiliate with any other charitable institutions.
5. To do all such other lawful things as are necessary for the attainment of the above objectives.

The summary of main activities in relation to the charity objectives are as follows:

- Annual Scientific Meeting
- Provision of travel grants
- Provision of meeting awards
- Allocation of research grants in association with Neuroendocrine Cancer UK
- Provision of educational activities (webinars and NET for Newcomers training day)
- Guideline development
- Public engagement in association with Neuroendocrine Cancer UK

### **Achievements and performance**

#### **UKI NETS 21st Annual Conference: Sheffield**

The 21st Annual Conference of the Society was held at Cutlers Hall in Sheffield on Monday 4 December 2023.

The programme contained sessions focused on: Multi-Disciplinary Challenges in Clinical Practice; a clinical trials overview; a debate on Liver Transplant as an option for patients with neuroendocrine neoplasms; a challenging the experts live NET MDT session; a NET translational medicine session and an international plenary on Treatment beyond 4 cycles of PRRT. Posters and oral communications were presented. The conference ended with a Prize Giving session. Satellite symposia were also held by sponsors.

## **TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2024**

### **Provision of travel grants**

Five travel grants were awarded to the presenters of the best scoring abstracts for the conference (excluding physicians in post more than 5 years). Four were awarded free membership for a year; one current member was awarded £100.

### **Provision of meeting awards**

Prizes were awarded to the top three best scoring clinical and scientific posters and the best oral communication at the 21<sup>st</sup> Annual Conference.

### **Provision of Research grants**

Neuroendocrine Cancer UK (NCUK), in association with UKINETS, awarded two practice changing grants of £10k each to find new and practical ways to improve the lives and experiences of people with neuroendocrine cancer.

### **Public Engagement**

UKI NETS members have been involved with and supporting the Neuroendocrine Cancer UK awareness campaign for healthcare professionals and the development of a care pathway.

### **Educational activities**

NETs for Newcomers:

On 23<sup>rd</sup> May 2024 UKINETS presented the seventh annual one day course for doctors and HCPs of all specialties who wished to learn more about Neuroendocrine Tumours. It was held face to face in Oxford. The course was delivered by an expert multidisciplinary faculty and included 'mock MDT' practice in small groups. Approximately 43 HCPs attended and feedback was very positive. 6 CPD points were awarded to attendees.

Webinars:

UKINETS continued to deliver its series of educational webinars, led by the Education and Training Committee. Webinars were delivered on the new NET Pathway, Carcinoid Heart Disease and Pancreatic Neuroendocrine Neoplasms. The webinars are free to attend for both members and non-members of UKINETS and the society intends to continue delivering three per year.

### **Guideline development**

The UKINETS Clinical Practice Committee continues to create clinical guideline documents for its Bitesize Guidance library, available on the UKINETS website. As well as the creation of new guidance, existing guidance was reviewed and updated.

### **Dietitians' Working Group**

The chair of the dietitians' working group remained as a co-optee on the Executive Committee. The group delivered a dietetic study day for November 2023. At the 2024 Executive Committee elections, the Dietitian/AHP Rep was made an official elected position on the Executive Committee.

### **Sponsor Support**

There was financial support to the Society in the form of sponsorship from companies throughout the pharmaceutical industry. The majority of the funding was provided as sponsorship for the National Conference and NETs for Newcomers Training Day. Sponsorship packages were developed by the Treasurer to give companies options for different levels and areas of support moving forwards.

## **TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2024**

### **Website**

The charity's website provides an important tool to inform members and the general public about the activities of the Society, as well as updates in NET research. <http://www.ukinets.org>.

### **Communications**

UKI NETS communicates with its members by means of a e-newsletter delivering news from the Society and the wider field. In addition, the charity highlights on its website news and research relating to the field of neuroendocrine tumours. The charity also has its own Twitter account @UKINETTS. The Society is in the process of investigating the use of other social networks.

### **Clinical Trials**

The members of the recently disbanded NCRI NET Clinical Studies Group, which monitored and compiled summaries of clinical trials, joined the UKINETTS Research SubCommittee.

### **Link with the European Neuroendocrine Tumour Society (ENETS)**

UKI NETS continues to provide optional inclusive membership to its members to its European partner Society, ENETS. Through membership of ENETS, UKI NETS members have access to *Journal of Neuroendocrinology* and a reduced rate for the ENETS annual conference. A member of UKINETTS sits on the Executive Committee of ENETS.

### **Financial review**

#### **Principal funding sources**

Income to the Society is mainly generated through industry support, the annual conference and membership subscriptions. Personal donations/legacies are received on an ad hoc basis.

## **TRUSTEES REPORT (INCLUDING DIRECTORS REPORT YEAR ENDED 31 AUGUST 2024**

### **Reserves policy**

The reserve policy takes into consideration the major risks that could face the Society.

It is the policy of the Society to maintain unrestricted funds, which are the free reserves of the charity. The reserves are held at a level that ensures the financial viability of the Society. That level is deemed to be one that equates to a minimum of two years' expenditure. The balance sheet indicates that there are £183,990 unrestricted funds as at 31 August 2024. This provides sufficient funds to cover management, administration and support costs.

### **Plans for future periods**


The UKI NETS 22<sup>nd</sup> Annual Conference is scheduled to be held in Cardiff in December 2024.

Abstracts have been submitted as usual and prizes will be awarded to the highest scoring presentations during the conference.

Other plans for the coming year include:

- Holding the third International Symposium on Carcinoid Heart Disease the day after the UKINETS Annual Conference in Sheffield
- Awarding 2 x Pump Priming Grants on behalf of NCUK in December 2024
- Holding a further NETs for Newcomers training event in Manchester in May 2025
- Holding a joint conference with NCUK on Molecular Radiotherapy in November 2024
- Further developing the library of bite size clinical guidance for the website
- Continuing the delivery of a programme of free educational webinars on varied topics relating to NETs – to improve education and awareness for HCPs
- Developing a national NET database for research purposes
- Continued liaison with NHS England to organise specialised commissioning for NETs
- Providing feedback on external clinical guidelines
- Continuing to secure funding from corporate donors
- Continuing to develop communications with members

The Trustees Report was approved by the Board of Trustees and signed on its behalf by:

Dr T H Shah 

Trustee

Dated: 25/01/2025

## **INDEPENDENT EXAMINERS REPORT TO THE TRUSTEES OF UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**

I report to the trustees on my examination of the financial statements of UK and Ireland Neuroendocrine Tumour Society Limited for the year ending 31 August 2024.

### **Responsibilities and basis of report**

As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).

Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for an independent examination. I report in respect of the examination of the charity's financial statements carried out under section 144 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

### **Independent Examiner's Statement**

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
- the financial statements do not accord with those records; or
- the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
- the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).;

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Andrew Hopkins  
BVSC Accountancy Services  
Latham House, 33-34 Paradise Street  
Birmingham, B1 2AJ

Dated: 20 February 2025

UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND EXPENDITURE ACCOUNT)  
YEAR ENDED 31 AUGUST 2024

	Note	Unrestricted funds 2024	Restricted funds 2024	Total 2024	Total 2023
		£	£	£	£
<b><u>Income from:</u></b>					
Donations and legacies	3	23,252	-	23,252	7,047
<b><u>Charitable activities</u></b>					
Sponsorship	4	114,228	-	114,228	50,587
Grants	4	-	-	-	-
<b>Total income</b>		<b>137,480</b>	<b>-</b>	<b>137,480</b>	<b>57,634</b>
<b><u>Expenditure on:</u></b>					
<b><u>Charitable activities</u></b>					
Research grant		-	-	-	-
Other charitable expenditure	5	121,922	-	121,922	70,074
<b>Total charitable expenditure</b>		<b>121,922</b>	<b>-</b>	<b>121,922</b>	<b>70,074</b>
Other resources expended		-	-	-	15
<b>Total resources expended</b>		<b>121,922</b>	<b>-</b>	<b>121,922</b>	<b>70,089</b>
<b>Net income for the year/Net movement in funds</b>		<b>15,559</b>	<b>-</b>	<b>15,559</b>	<b>- 12,455</b>
<b>Fund balances at 1 September 2023</b>		<b>141,436</b>	<b>5,464</b>	<b>146,900</b>	<b>159,355</b>
Transfers in funds		-	-	-	-
<b>Fund balances at 31 August 2024</b>		<b>156,995</b>	<b>5,464</b>	<b>162,459</b>	<b>146,900</b>

The statement of financial activities also complies with the requirements for an income and expenditure accounts under the Companies Act 2006

**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**

**BALANCE SHEET  
YEAR ENDED 31 AUGUST 2024**


	Notes	2024 £	2023 £
<b>Fixed Assets</b>			
<b>Tangible Assets</b>	<b>3</b>	-	-
<b>Current Assets</b>			
Cash at Bank		137,060	120,293
Debtors	4	<u>31,254</u>	<u>36,089</u>
		<b>168,314</b>	<b>156,382</b>
<b>Creditors</b>			
Amounts falling due within one year	5	5,855	9,482
		<u>162,459</u>	<u>146,900</u>
<b>Net Current Assets</b>		<b>162,459</b>	<b>146,900</b>
<b>Total Current Assets less Current Liabilities</b>		<u><b>162,459</b></u>	<u><b>146,900</b></u>
<b>Capital and Reserves</b>			
Restricted funds	6	5,464	5,464
Unrestricted funds	6	156,995	141,436
		<u><b>162,459</b></u>	<u><b>146,900</b></u>

For the year ending 31 August 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. No members have required the company to obtain an audit of the financial statements for the year ending 31 August 2024 in accordance with section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for ensuring that the charity keeps accounting records which comply with section 386 of the Act and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its incoming resources and application of resources, including its income and expenditure, for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and signed on behalf of the board by:

Signature: 

Name: Prof R Srirajaskanthan, UKINETS Treasurer

Date: 28 March 2025

**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**YEAR ENDED 31 AUGUST 2024**

**1. Accounting Policies**

**Accounting convention**

The accounts have been prepared in accordance with the Companies Act 2006 and “Accounting and Reporting by Charities: Statement of Recommended Practice (SORP) applicable in the UK and Republic of Ireland (FRS 102)” (as amended for accounting periods commencing from 1 January 2016). The charity is a “Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charity.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

**Going concern**

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis if accounting in preparing the financial statements.

**Charitable funds**

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

**Incoming resources**

These are included in the Statement of Financial Activities (SOFA) when:

- The charity becomes legally entitled to the resources after any performance conditions have been met;
- The trustees are virtually certain that they will receive the resources; and
- The monetary value can be measured with sufficient reliability.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount.

Charitable income includes sponsorship of the annual conference and contributions towards the charity’s objectives.

# UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

### YEAR ENDED 31 AUGUST 2024

#### 1. Accounting Policies (continued)

##### **Resources expended**

Charitable activities includes all costs relating to the conference, newsletters and general administration, which support the charitable purpose.

Grants offered subject to conditions, which have not been met at the year-end date are noted as a commitment, but not accrued as expenditure.

Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Where costs cannot be directly attributed to particular headings that have been allocated to activities on a basis consistent with the use of the resources.

##### **Incoming resources with related expenditure**

When incoming resources have related expenditure (as with fundraising or contract income) both are reported gross in the SOFA.

##### **Tangible fixed assets**

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values their useful lives on the following bases:

Computers – straight line over 3 years

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in net income/(expenditure) for the year.

##### **Cash and cash equivalents**

Cash and cash equivalents include cash in hand, deposits held at call with bankers, other short term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

##### **Financial instruments**

The charity has elected to apply the provisions of Section 11 “Basic Financial Instruments” and Section 12 “Other Financial Issues” of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity’s balance sheet when the charity becomes party to the contractual provisions of the instrument.

**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**YEAR ENDED 31 AUGUST 2024**

**1. Accounting Policies (continued)**

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the assets and settle the liability simultaneously.

***Basic financial assets***

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price, including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market value of interest. Financial assets classified as receivable within one year are not amortised.

***Basic financial liabilities***

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

***De-recognition of financial liabilities***

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

**2. Critical accounting estimates and judgements**

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

NOTES TO THE FINANCIAL STATEMENTS  
YEAR ENDED 31 AUGUST 2024

**3 Donations and legacies**

	<b>Unrestricted funds 2024 £</b>	<b>Restricted funds 2024 £</b>	<b>Total 2024 £</b>	<b>Total 2023 £</b>
Donations and gifts	4,350		4,350	952
Membership fees	18,902	-	18,902	6,095
Total for the year	<u>23,252</u>	<u>-</u>	<u>23,252</u>	<u>7,047</u>

**4 Charitable activities (income)**

	<b>Sponsorship 2024 £</b>	<b>Grants 2024 £</b>	<b>Total 2024 £</b>	<b>Total 2023 £</b>
Sales within charitable activities	114,228	-	114,228	50,587
Performance related grants	-	-	-	-
Total for the year	<u>114,228</u>	<u>-</u>	<u>114,228</u>	<u>50,587</u>

**Analysis by fund**

Unrestricted funds	114,228	-	114,228	50,587
Restricted funds	-	-	-	-
	<u>114,228</u>	<u>-</u>	<u>114,228</u>	<u>50,587</u>

**5 Charitable activities (expenditure)**

	<b>Total 2024 £</b>	<b>Total 2023 £</b>
Depreciation and impairment	-	-
Conferences and newsletters	70,308	12,772
Application development costs	-	3,600
Total for the year	<u>70,308</u>	<u>16,372</u>

Share of support costs (note 6)	23,826	24,568
Share of governance costs (note 6)	27,787	29,135
	<u>121,922</u>	<u>70,075</u>

**Analysis by fund**

Unrestricted funds	121,922	70,075
Restricted funds	-	-
	<u>121,922</u>	<u>70,075</u>

**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**

**NOTES TO THE FINANCIAL STATEMENTS  
YEAR ENDED 31 AUGUST 2024**

**6 Support costs**

	<b>Support costs 2024 £</b>	<b>Governance costs 2024 £</b>	<b>Total 2024 £</b>	<b>Total 2023 £</b>
ENET membership subscriptions	5,643		5,643	8,426
Website	5,095		5,095	2,592
Management fees	13,088		13,088	13,550
Independent examiner and accountancy fees		1,160	1,160	1,680
Other operating costs		26,500	26,500	27,455
Committee meetings		127	127	-
	<u>23,826</u>	<u>27,787</u>	<u>51,613</u>	<u>53,703</u>
<b>Analysis by fund</b>				
Unrestricted funds	23,826	27,787	51,613	53,703
Restricted funds	-	-	-	-
	<u>23,826</u>	<u>27,787</u>	<u>51,613</u>	<u>53,703</u>

**7 Trustees**

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year (2023 - £nil).

**8 Employees**

There were no employees during the year. (2023 – nil).

**9 Tangible fixed assets**

<b>Cost</b>	<b>Computers £</b>
At 1 September 2023	-
At 31 August 2024	<u>-</u>
	<u>-</u>
<b>Depreciation and impairment</b>	
At 1 September 2023	-
At 31 August 2024	<u>-</u>
	<u>-</u>
<b>Carrying amount</b>	
At 31 August 2024	<u>-</u>
	<u>-</u>
At 31 August 2023	<u>-</u>

UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

NOTES TO THE FINANCIAL STATEMENTS  
YEAR ENDED 31 AUGUST 2024

10 Financial instruments

	2024	2023
	£	£
<b>Carrying amount of financial assets</b>		
Debt instruments measured at amortised cost	<u>-</u>	<u>-</u>
<b>Carrying value of financial liabilities</b>		
Measured on amortised costs	<u>-</u>	<u>-</u>

11 Debtors

	2024	2023
	£	£
Amount due from Bioscientifica	-	29,971
Prepayments	<u>31,254</u>	<u>6,117</u>
	<u>31,254</u>	<u>36,088</u>

12 Creditors: amounts falling due within one year

	2024	2023
	£	£
Deferred income	-	-
Other creditors	-	3,996
Accruals	<u>5,855</u>	<u>5,486</u>
	<u>5,855</u>	<u>9,482</u>

13 Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Balance at 1 September 2023	Incoming resources	Resources expended	Transferred to unrestricted	Balance at 31 August 2024
	£	£	£	£	£
TransNET	3,268		-	-	3,268
Mobile app development	<u>2,195</u>	-	-	-	<u>2,195</u>
	<u>5,464</u>	-	-	-	<u>5,463</u>

Funds de-restricted were evident to have been spent in prior years based on comparison with the tracked fund balances.

14 Analysis of net assets between funds

Fund balances at 31 August 2024 and 31 August 2023 are represented by current assets/(liabilities).

15 Related party transaction

There were no disclosable related party transactions during the year (2023 – none).

**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY**

England & Wales - Charity number 1148145

---

# Accounts

---

# UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

---

## TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2023

The trustees, who are also directors of the charity for the purposes of the Companies Act 2006, present their report and unaudited financial statements of the charity for the year ending 31 August 2023.

### Trustees

The trustees, who are also the directors for the purposes of company law, and who served during the year and up to the date of signature of the unaudited financial statements were:

Prof J Newell-Price – retired 31 May 2023

Dr T H Shah

Prof C Thirlwell

Prof M Pritchard

None of the directors has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £1 in the event of winding up.

### Governing document

The UK and Ireland Neuroendocrine Tumour Society Limited (UKI NETS) is constituted by its Memorandum & Articles of Association, adopted by the membership on 7 December 2015, and is a registered charity. UKI NETS became a company limited by guarantee on 13 August 2008 and was subsequently registered as a charity on 16 July 2012.

### Organisational structure

The Society has four main categories of membership as follows: Clinician; Scientist; Nurse and Allied Health Professional Members. Each of these categories is broken down into career stages. All members are given the option of membership with or without inclusive ENETS membership. Membership of the charity is open to any medical professionals or scientists interested in promoting the objects.

The Society is governed by four Executive Officers, who are the directors and trustees (Chair, Past Chair or Chair-elect, Treasurer and Secretary), supported by a wider Executive Committee, which includes chairs of the sub committees. The role of Chair-elect was introduced in 2023 to ensure continuity of knowledge and experience. The Articles of Association are to be updated accordingly by Special Resolution at the AGM on 4 December 2023.

### Risk management

The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error.

## TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2023

### Objectives and activities

The charity's objects are to promote for the public benefit research, education and clinical practice in neuroendocrine tumours by the organisation of conferences, training courses and publications, by raising public awareness, liaison with national and international legislators, and by any other appropriate means. The Society aims to improve the diagnosis and therapy of patients with neuroendocrine tumours within a national multidisciplinary and scientific context.

In furtherance of its objects, the Society shall have the following powers:

1. To arrange and provide for the holding of meetings, lectures and seminars.
2. To procure to be written and print, publish, issue and circulate gratuitously or otherwise such papers, periodicals, pamphlets or other documents.
3. To raise funds and to invite and receive contributions from any person or persons whatsoever by way of subscriptions and otherwise provided that the Society shall not undertake any permanent trading activities in raising funds for its primary charitable objectives.
4. To co-operate, associate or affiliate with any other charitable institutions.
5. To do all such other lawful things as are necessary for the attainment of the above objectives.

The summary of main activities in relation to the charity objectives are as follows:

- Annual Scientific Meeting
- Provision of travel grants
- Provision of meeting awards
- Allocation of research grants
- Provision of educational activities
- Guideline development
- Public engagement

### Achievements and performance

#### UKI NETS 20<sup>th</sup> Annual Conference; London

The 20th Annual Conference of the Society was held at the Royal College of Physicians in London on Monday 5 December 2022. This was the first time the conference had been held face to face since the COVID-19 pandemic. The sessions were also recorded for virtual viewing after the event. The Society welcomed 191 people to the event (17 on demand only).

The programme contained sessions focused on: Multi Disciplinary Challenges in Clinical Practice; a clinical trials overview; a debate on the dilemma regarding Somatostatin Analogue discontinuation in non-functional NETs; a challenging the experts live NET MDT session; case presentations; a NET translational medicine session. Oral abstract presentations included topics such as Urine 5-HIAA levels and Quality-of-Life in Neuroendocrine Neoplasia; Glucagonomas; diagnostic features and outcomes of first line treatment in a series of 18 patients and Outcomes in patients with advanced well-differentiated gastroenteropancreatic neuroendocrine tumours receiving PRRT early vs later. The conference ended with a Prize Giving session. Satellite symposia were also held by sponsors.

# UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

---

## TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2023

### Provision of travel grants

Ten travel grants were awarded to the presenters of the best scoring abstracts for the conference (excluding physicians in post more than 5 years). Seven were awarded free membership for a year; three current members were awarded £100.

### Provision of meeting awards

Prizes were awarded to the top three best scoring clinical and scientific posters and the best oral communication at the 20<sup>th</sup> Annual Conference.

### Provision of Research grants

Neuroendocrine Cancer UK (NCUK), in association with UKINETS, awarded one research grant of £30k to provide pump-priming funds to support a research project aimed at improving outcomes for patients with Neuroendocrine Tumours.

### Public Engagement

UKI NETS members have been involved with and supporting the Neuroendocrine Cancer UK awareness campaign for healthcare professionals and the development of a care pathway.

### Educational activities

#### NETs for Newcomers:

On 18th May 2023 UKINETS presented the sixth annual one day course for doctors of all specialties who wished to learn more about Neuroendocrine Tumours. It was held face to face in Birmingham, following two years virtually due to the Covid-19 pandemic. The course was delivered by an expert multidisciplinary faculty and included 'mock MDT' practice in small groups. Approximately 34 HCPs attended and feedback was very positive. Presentations were made available to all members via the online-members area following the event.

#### Webinars:

UKINETS has developed a series of educational webinars, led by the Education and Training Committee. The first webinar was on the topic of Nutrition in NETs and the second was on Liver Transplantation in NETs. The webinars are free to attend for both members and non-members of UKINETS and the society intends to deliver three per year.

### Dietitians' Working Group

The chair of the dietitians' working group remained as a co-optee on the Executive Committee. The group compiled bitesize guidance for PEI, BAD, Insulinoma and bowel obstruction and planned a dietetic study day for November 2023.

### Sponsor Support

There was financial support to the Society in the form of sponsorship from companies throughout the pharmaceutical industry. The majority of the funding was provided as sponsorship for the National Conference and NETs for Newcomers Training Day. Sponsorship packages were developed by the Treasurer to give companies options for different levels and areas of support moving forwards.

# UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

---

## TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2023

### Website

The charity's website provides an important tool to inform members and the general public about the activities of the Society. <http://www.ukinets.org>.

### Communications

UKI NETS communicates with its members by means of a newsletter news from the Society and the wider field. In addition, the charity highlights on its website news and research relating to the field of neuroendocrine tumours. The charity also has its own Twitter account @UKINETS.

### Liver transplantation delivery programme

The development of a liver transplantation delivery programme and associated service development and research opportunities was delivered by UKI NETS in collaboration with LAG, NHSBT and SIGTO. Progress was made in 2023 with the initial four live transplants planned for October/November 2023 at Birmingham, King's and Royal Free.

### Clinical Trials

The recently disbanded NCRI NET Clinical Studies Group, which monitored and compiled summaries of clinical trials, presented updates and reports at the UKINETS Annual Conference. The Research SubCommittee of UKINETS also aims to keep the UKINETS website and NCUK up to date with trials that are currently recruiting.

### Link with the European Neuroendocrine Tumour Society (ENETS)

UKI NETS continues to provide inclusive membership to its members to its European partner Society, ENETS (optional). Through membership of ENETS, UKI NETS members have access to *Journal of Neuroendocrinology* and a reduced rate for the ENETS annual conference. A member of UKINETS sits on the Executive Committee of ENETS.

### Financial review

#### Principal funding sources

Income to the Society is mainly generated through industry support, the annual conference and membership subscriptions. Personal donations/legacies are received on an ad hoc basis.

**TRUSTEES REPORT (INCLUDING DIRECTORS REPORT  
YEAR ENDED 31 AUGUST 2023**

**Reserves policy**

The reserve policy takes into consideration the major risks that could face the Society.

It is the policy of the Society to maintain unrestricted funds, which are the free reserves of the charity. The reserves are held at a level that ensures the financial viability of the Society. That level is deemed to be one that equates to a minimum of two years' expenditure. The balance sheet indicates that there are £113,375 unrestricted funds as at 31 August 2023. This provides sufficient funds to cover management, administration and support costs.

**Plans for future periods**

The UKI NETS 21st Annual Conference is scheduled to be held in Sheffield in December 2023.

Abstracts have been submitted as usual and prizes will be awarded to the highest scoring presentations during the conference.

Other plans for the coming year include:

- Holding the third International Symposium on Carcinoid Heart Disease the day after the UKINETS Annual Conference in Sheffield.
- Awarding 2 x £10k Practice Changing Grants on behalf of NCUK in December 2023.
- Holding a further NETs for Newcomers training event in Oxford in May 2024.
- Holding a NET dietetics study day in Birmingham in November 2023.
- Further developing the library of bite size clinical guidance for the website and reviewing older guidelines
- Continuing the delivery of a programme of free educational webinars on varied topics relating to NETs – to improve education and awareness for HCPs.
- Providing feedback on external clinical guidelines
- Continuing to secure funding from corporate donors
- Continuing to develop communications with members
- Inviting members of the disbanded NCRI NET Clinical Studies Group to join the UKINETS Research Subcommittee

The Trustees Report was approved by the Board of Trustees and signed on its behalf by:

Dr T H Shah

Trustee

Dated



01/05/2024

# UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

---

## INDEPENDENT EXAMINERS REPORT TO THE TRUSTEES OF UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

I report to the trustees on my examination of the financial statements of UK and Ireland Neuroendocrine Tumour Society Limited for the year ending 31 August 2023.

### Responsibilities and basis of report

As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).

Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for an independent examination, I report in respect of the examination of the charity's financial statements carried out under section 144 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

### Independent Examiner's Statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or

the financial statements do not accord with those records; or

the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or

the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102);

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Andrew Hopkins  
BVSC Accountancy Services  
Latham House  
33-34 Paradise Street  
Birmingham  
B1 2AJ



Dated: 23/3/2024

## UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

### STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND EXPENDITURE ACCOUNT) YEAR ENDED 31 AUGUST 2023

	Not e	Unrestrict ed funds 2023 £	Restricted funds 2023 £	Total 2023 £	Total 2022 £
<b><u>Income from:</u></b>					
Donations and legacies	3	6,775	272	17,047	20,108
<b><u>Charitable activities</u></b>					
Sponsorship	4	50,587	-	50,587	77,784
Grants	4	-	-	-	-
<b>Total Income</b>		<b>57,634</b>	<b>272</b>	<b>57,634</b>	<b>97,892</b>
<b><u>Expenditure on:</u></b>					
<b><u>Charitable activities</u></b>					
Research grant		-	-	-	-
Other charitable expenditure	5	70,074	-	70,074	86,061
<b>Total charitable expenditure</b>		<b>70,074</b>	<b>-</b>	<b>70,074</b>	<b>86,061</b>
Other resources expended		15	-	15	36
<b>Total resources expended</b>		<b>70,089</b>	<b>-</b>	<b>70,089</b>	<b>86,097</b>
<b>Net income for the year/Net movement in funds</b>		<b>-12,727</b>	<b>272</b>	<b>-12,455</b>	<b>11,795</b>
<b>Fund balances at 1 September 2022</b>		<b>135,830</b>	<b>23,625</b>	<b>159,355</b>	<b>147,560</b>
<b>Transfers between funds</b>		<b>18,334</b>	<b>-18,334</b>	<b>-</b>	<b>-</b>
<b>Fund balances at 31 August 2023</b>		<b>141,436</b>	<b>5,463</b>	<b>146,900</b>	<b>159,355</b>

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

# UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

## BALANCE SHEET AS AT 31 AUGUST 2023

	Notes	2023 £	2022 £
<b>Fixed Assets</b>			
<b>Tangible Assets</b>	3	0	0
<b>Current Assets</b>			
Cash at Bank		120,293	115,983
Debtors	4	36,088	49,918
		<u>156,382</u>	<u>165,901</u>
<b>Creditors</b>			
Amounts falling due within one year	5	9,481	6,546
		<u>146,900</u>	<u>159,355</u>
<b>Net Current Assets</b>		<u>146,900</u>	<u>159,355</u>
<b>Total Current Assets less Current Liabilities</b>		<u>146,900</u>	<u>159,355</u>
<b>Capital and Reserves</b>			
Restricted funds	6	5,464	23,525
Unrestricted funds	6	141,436	135,830
		<u>146,900</u>	<u>159,355</u>


For the year ending 31 August 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. No members have required the company to obtain an audit of the financial statements for the year ending 31 August 2023 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for ensuring that the charity keeps accounting records which comply with section 386 of the Act and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its incoming resources and application of resources, including its income and expenditure, for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees on  
signed on behalf of the board by:

Emil T.H. Shah, Trustee

  
01/25/2024 8

, and

**NOTES TO THE FINANCIAL STATEMENTS  
YEAR ENDED 31 AUGUST 2023**

**1. Accounting Policies**

**Accounting convention**

The accounts have been prepared in accordance with the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice (SORP) applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016). The charity is a "Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charity.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

**Going concern**

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

**Charitable funds**

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

**Incoming resources**

These are included in the Statement of Financial Activities (SOFA) when:

- The charity becomes legally entitled to the resources after any performance conditions have been met;
- The trustees are virtually certain that they will receive the resources; and
- The monetary value can be measured with sufficient reliability.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount.

Charitable income includes sponsorship of the annual conference and contributions towards the charity's objectives.

# UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

---

## NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2023

### 1. Accounting Policies (continued)

#### Resources expended

Charitable activities includes all costs relating to the conference, newsletters and general administration, which support the charitable purpose.

Grants offered subject to conditions, which have not been met at the year-end date are noted as a commitment, but not accrued as expenditure.

Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Where costs cannot be directly attributed to particular headings that have been allocated to activities on a basis consistent with the use of the resources.

#### Incoming resources with related expenditure

When incoming resources have related expenditure (as with fundraising or contract income) both are reported gross in the SOFA.

#### Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values their useful lives on the following bases:

Computers – straight line over 3 years

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in net income/(expenditure) for the year.

#### Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with bankers, other short term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

#### Financial Instruments

The charity has elected to apply the provisions of Section 11 "Basic Financial Instruments" and Section 12 "Other Financial Issues" of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

# UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2023

### 1. Accounting Policies (continued)

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the assets and settle the liability simultaneously.

#### **Basic financial assets**

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price, including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market value of interest. Financial assets classified as receivable within one year are not amortised.

#### **Basic financial liabilities**

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

#### **De-recognition of financial liabilities**

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

### 2. Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

### 3. Donations and legacies

	Unrestricted Funds	Restricted funds	Total	Total
	2023 £	2023 £	2023 £	2022 £
Donations and gifts	680	272	952	-
Membership fees	6,095	-	6,095	20,108
Total for the year	<u>6,775</u>	<u>272</u>	<u>7,047</u>	<u>20,108</u>

# UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2023

### 4. Charitable activities

	Sponsorship	Grants	Total	Total
	2023	2023	2023	2022
	£	£	£	£
Sales within charitable activities	50,587	-	50,587	77,784
Performance related grants	-	-	-	-
<b>Total for the year</b>	<b>50,587</b>	<b>-</b>	<b>50,587</b>	<b>77,784</b>

### Analysis by fund

Unrestricted funds	50,587	-	40,587	77,784
Restricted funds	-	-	10,000	-
	<b>50,587</b>	<b>-</b>	<b>50,587</b>	<b>77,784</b>

### 5. Charitable activities

	2023	2022
	£	£
Depreciation and Impairment	-	-
Conferences and newsletters	12,972	31,919
Application developments costs	3,600	-
	<b>16,572</b>	<b>31,919</b>
Share of support costs (note 6)	24,368	23,876
Share of governance costs (note 6)	29,135	30,266
	<b>70,089</b>	<b>86,061</b>

### Analysis by fund

Unrestricted funds	70,089	86,061
Restricted funds	-	-
	<b>70,089</b>	<b>86,061</b>



# UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2023

### 10. Financial Instruments

	2023 £	2022 £
<b>Carrying amount of financial assets</b>		
Debt instruments measured at amortised cost	<u>          -</u>	<u>          -</u>
<b>Carrying value of financial liabilities</b>		
Measured on amortised costs	<u>          -</u>	<u>          -</u>

### 11. Debtors

	2023 £	2022 £
Amount due from Bio	29,971	36,318
Prepayments	6,117	13,600
	<u>36,088</u>	<u>49,918</u>

### 12. Creditors: amounts falling due within one year

	2023 £	2022 £
Deferred income	0	0
Other creditors	3,996	2,840
Accruals and deferred income	5,486	3,706
	<u>9,481</u>	<u>6,546</u>

### 13. Other deferred Income

	2023 £	2022 £
Other deferred income	<u>          -</u>	<u>          -</u>

# UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2023

### 14. Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Movement in funds				
	Balance at 1 September 2022	Incoming resources	Resources expended	Resources transferred to unrestricted	Balance at 31 August 2023
	£	£	£	£	£
Grants	11,150	-	-	11,150	-
TransNET	4,925	272	-	1,929	3,268
Mobile app development	7,450	-	-	5,255	2,195
	<u>23,525</u>	<u>272</u>	<u>-</u>	<u>18,334</u>	<u>5,464</u>

Funds de-restricted were evident to have been spent in prior years based on comparison with the tracked fund balances.

### 15. Analysis of net assets between funds

Fund balances at 31 August 2023 and 31 August 2022 are represented by current assets/(liabilities).

### 16. Related party transaction

There were no disclosable related party transactions during the year (2022 – none).

**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY**

England & Wales - Charity number 1148145

---

# Accounts

---

**Charity Registration Number: 1148145**

**Company Registration Number: 06672185 (England and Wales)**

**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**

**UNAUDITED FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED 31 AUGUST 2022**

## CONTENTS

	<b>Page</b>
Legal and administrative information	2
Trustees' Report	3 to 7
Independent examiners report	8
Statement of financial activities	9
Balance sheet	10
Notes to the financial statements	11 to 17

**LEGAL AND ADMINISTRATIVE INFORMATION**

**Trustees**

Prof J Newell-Price - resigned 01/12/2021

Prof M Pritchard - appointed 01/12/2021

Prof J Ramage - retired 06/12/2021

Prof T H Shah

Prof C Thirlwell

**Registered Office**

First Floor

Livery Place

35 Livery Street

Birmingham

B3 2PB

**Charity number:** 1148145

**Company number:** 06672185 (registered in England and Wales)

**Independent Examiner**

Jasbir Rai

BVSC Accountancy Services

First Floor

Livery Place

35 Livery Street

Birmingham

B3 2PB

## TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2022

The trustees, who are also directors of the charity for the purposes of the Companies Act 2006, present their report and unaudited financial statements of the charity for the year ending 31 August 2022.

### Trustees

The trustees, who are also the directors for the purposes of company law, and who served during the year and up to the date of signature of the unaudited financial statements were:

Prof J Newell-Price - resigned 01/12/2021

Prof M Pritchard - appointed 01/12/2021

Prof J Ramage - retired 06/12/2021

Prof T H Shah

Prof C Thirlwell

None of the directors has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £1 in the event of winding up.

The Society has two main categories of membership as follows: Clinician and Consultant Members; Trainee, Nurse, Scientist and Allied Health Professional Members. The latter are given the option of membership with or without inclusive ENETS membership. Membership of the charity is open to any medical professionals or organisations interested in promoting the objects.

### Governing document

The UK and Ireland Neuroendocrine Tumour Society Limited (UKI NETS) is constituted by its Memorandum & Articles of Association, adopted by the membership on 1 December 2014, and is a registered charity. UKI NETS became a company limited by guarantee on 13 August 2008 and was subsequently registered as a charity on 16 July 2012.

### Organisational structure

The Society has two main categories of membership as follows: Clinician and Consultant Members; Trainee, Nurse, Scientist and Allied Health Professional Members. The latter are given the option of membership with or without inclusive ENETS membership. Membership of the charity is open to any medical professionals or organisations interested in promoting the objects.

The Society is governed by four Executive Officers, who are the directors and trustees (Chair, Past Chair, Treasurer and Secretary), supported by a wider Executive Committee, which includes chairs of the sub committees.

### Risk management

The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error.

## TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2022

### Objectives and activities

The charity's objects are to promote for the public benefit research, education and clinical practice in neuroendocrine tumours by the organisation of conferences, training courses and publications, by raising public awareness, liaison with national and international legislators, and by any other appropriate means. The Society aims to improve the diagnosis and therapy of patients with neuroendocrine tumours within a national multidisciplinary and scientific context.

In furtherance of its objects, the Society shall have the following powers:

1. To arrange and provide for the holding of meetings, lectures and seminars.
2. To procure to be written and print, publish, issue and circulate gratuitously or otherwise such papers, periodicals, pamphlets or other documents.
3. To raise funds and to invite and receive contributions from any person or persons whatsoever by way of subscriptions and otherwise provided that the Society shall not undertake any permanent trading activities in raising funds for its primary charitable objectives.
4. To co-operate, associate or affiliate with any other charitable institutions.
5. To do all such other lawful things as are necessary for the attainment of the above objectives.

The summary of main activities in relation to the charity objectives are as follows:

- Annual Scientific Meeting
- Provision of travel grants
- Provision of meeting awards
- Allocation of research grants
- Provision of educational activities
- Guideline development
- Public engagement

### Achievements and performance

#### UKI NETS 19<sup>th</sup> Annual Conference: Online 2021

The 19th Annual Conference of the Society was held Online on Monday 6 to Tuesday 7 December 2021. This was the second time that the conference had been held virtually, due to the COVID-19 pandemic. The Society welcomed 182 people to the event. Content was provided on-demand to delegates following the conference.

Sessions ran from morning until early afternoon both days. The programme contained sessions focused on: challenges in clinical practice; clinical trials overview; a debate regarding the use of PRRT for pancreatic NETs; the national pilot of liver transplantation in NETs; a challenging the experts live NET MDT session; NET translational medicine. Oral abstract presentations included topics such as Incidence, prevalence of survival of neuroendocrine neoplasia in England, Tracking circulating cell free tumour derived DNA in patients with neuroendocrine neoplasms and an update on the effects of debulking surgery and liver directed intra-arterial therapies on quality of life in patients with metastatic neuroendocrine tumours. The conference ended with a Prize Giving session. Satellite symposia were also held by sponsors.

## TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2022

### Provision of travel grants

As the conference was held online in 2021, no travel grants were awarded.

### Provision of meeting awards

Prizes were awarded to the top three best scoring clinical and scientific posters and the best oral communication at the 19<sup>th</sup> Annual Conference.

### Provision of Research grants

UKI NETS and the NET Patient Foundation awarded one research grant of £30k to provide pump-priming funds to support a research project aimed at improving outcomes for patients with Neuroendocrine Tumours.

### Public Engagement

UKI NETS members speak regularly at regional events aimed to help NET patients across the UK in collaboration with Neuroendocrine Cancer UK and other organisations.

### Educational activities

NETs for Newcomers:

On 12th May 2022 UKINETS presented the fifth annual one day course for doctors of all specialties who wished to learn more about Neuroendocrine Tumours. It was held virtually for the second time due to the ongoing Covid-19 pandemic. The course was delivered by an expert multidisciplinary faculty and included 'mock MDT' practice in small groups. Approximately 47 HCPs attended and feedback was very positive.

International Symposium on Carcinoid Heart Disease:

The Second International Symposium on Carcinoid Heart Disease was held in Birmingham on 2 September 2021 in collaboration with other organisations. Sessions covered: Aetiology and quantifying impact; Current Management of CHD; Surgical Management of CHD and Peri-operative Management and Future Care.

### Dietitians' Working Group

The chair of the dietitians' working group remained as a co-optee on the Executive Committee. The group worked on a survey, audit and nutrition guideline.

### Sponsor Support

There was financial support to the Society in the form of sponsorship from companies throughout the pharmaceutical industry. The majority of the funding was provided as sponsorship for the National Conference and NETs for Newcomers Training Day. Sponsorship packages were developed by the Treasurer to give companies options for different levels and areas of support moving forwards.

## TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2022

### Website

The charity's website provides an important tool to inform members and the general public about the activities of the Society. <http://www.ukinets.org>.

### Communications

UKI NETS communicates with its members by means of a newsletter containing highlights from previous conferences, information on clinical trials and other Society news. In addition, the charity highlights on its website news stories from the media relating to the field of neuroendocrine tumours. The charity also has its own Twitter account @UKINETS.

### Liver transplantation delivery programme

The development of a liver transplantation delivery programme and associated service development and research opportunities was delivered by UKI NETS in collaboration with LAG, NHFBT and SIGTO.

### Clinical Trials

The NET Clinical Studies Group which monitors and compiles summaries of clinical trials presents updates and reports at the UKINETS Annual Conference. The Research SubCommittee of UKINETS also aims to keep the UKINETs website and NET Patient Foundation up to date with trials that are currently recruiting.

### Link with the European Neuroendocrine Tumour Society (ENETS)

UKI NETS continues to provide inclusive membership to its members to its European partner Society, ENETS. Through membership of ENETS, UKI NETS members have access to the journal *Neuroendocrinology* and a reduced rate for the ENETS annual conference. This inclusive membership is optional for trainees, nurses, scientists and allied health professionals.

### Financial review

#### Principal funding sources

Income to the Society is mainly generated through industry support, the annual conference and membership subscriptions. Personal donations/legacies are received on an ad hoc basis.

## TRUSTEES REPORT (INCLUDING DIRECTORS REPORT YEAR ENDED 31 AUGUST 2022

### Reserves policy

The reserve policy takes into consideration the major risks that could face the Society.

It is the policy of the Society to maintain unrestricted funds, which are the free reserves of the charity. The reserves are held at a level that ensures the financial viability of the Society. That level is deemed to be one that equates to a minimum of two years' expenditure. The balance sheet indicates that there are £135831 unrestricted funds as at 31 August 2022. This provides sufficient funds to cover management, administration and support costs.

### Plans for future periods

The UKI NETS 20th Annual Conference is scheduled to be held face-to-face in December 2022 following two years of virtual meetings due to the coronavirus pandemic.

Abstracts have been submitted as usual and prizes will be awarded to the highest scoring presentations during the conference. Content will be available on-demand following the conference.

Other plans for the coming year include:

- Holding a further NETs for Newcomers training event in-person in May 2023.
- Further developing the library of bite size clinical guidance for the website and reviewing older guidelines
- Delivery of a programme of free educational webinars on varied topics relating to NETs – to improve education and awareness for HCPs.
- Providing feedback on external clinical guidelines
- Continuing to secure funding from corporate donors
- Continuing to develop communications with members

Working with other societies and foundations to fund and promote NETS knowledge and research

The Trustees Report was approved by the Board of Trustees and signed on its behalf by:

Dr T H Shah

Trustee



Dated:

30/04/2023

## INDEPENDENT EXAMINERS REPORT TO THE TRUSTEES OF UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

I report to the trustees on my examination of the financial statements of UK and Ireland Neuroendocrine Tumour Society Limited for the year ending 31 August 2022.J

### Responsibilities and basis of report

As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).

Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for an independent examination. I report in respect of the examination of the charity's financial statements carried out under section 144 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

### Independent Examiner's Statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
2. the financial statements do not accord with those records; or
3. the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).;

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Jasbir Rai ACMA  
BVSC Accountancy Services  
First Floor  
Livery Place  
35 Livery Street  
Birmingham  
B3 2PB



Dated: 20/04/23

# UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

## STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND EXPENDITURE ACCOUNT) YEAR ENDED 31 AUGUST 2022

	Note	Unrestricted funds 2022	Restricted funds 2022	Total 2022	Total 2021
		£	£	£	£
<b><u>Income from:</u></b>					
Donations and legacies	3	20,108	-	20,108	17,121
<b><u>Charitable activities</u></b>					
Sponsorship	4	77,784	-	77,784	78,045
Grants	4	-	-	-	-
<b>Total income</b>		<b>97,892</b>	<b>-</b>	<b>97,892</b>	<b>95,166</b>
<b><u>Expenditure on:</u></b>					
<b><u>Charitable activities</u></b>					
Research grant		-	-	-	-
Other charitable expenditure	5	86,061	-	86,061	85,705
<b>Total charitable expenditure</b>		<b>86,061</b>	<b>-</b>	<b>86,061</b>	<b>85,705</b>
Other resources expended		37	-	37	95
<b>Total resources expended</b>		<b>86,097</b>	<b>-</b>	<b>86,097</b>	<b>85,800</b>
<b>Net income for the year/Net movement in funds</b>		<b>11,795</b>	<b>-</b>	<b>11,795</b>	<b>9,366</b>
<b>Fund balances at 1 September 2021</b>		<b>124,035</b>	<b>23,525</b>	<b>147,560</b>	<b>147,560</b>
<b>Fund balances at 31 August 2022</b>		<b>135,830</b>	<b>23,525</b>	<b>159,355</b>	<b>147,560</b>

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

# UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

## BALANCE SHEET AS AT 31 AUGUST 2022

	Notes	2022 £	2021 £
<b>Fixed Assets</b>			
<b>Tangible Assets</b>	3	0	0
<b>Current Assets</b>			
Cash at Bank		115,983	98,765
Debtors	4	<u>49,918</u>	<u>64,327</u>
		165,901	163,092
<b>Creditors</b>			
Amounts falling due within one year	5	6,546	15,532
<b>Net Current Assets</b>		<u>159,355</u>	<u>147,560</u>
<b>Total Current Assets less Current Liabilities</b>		<u>159,355</u>	<u>147,560</u>
<b>Capital and Reserves</b>			
Restricted funds	6	23,525	23,525
Unrestricted funds	6	135,830	124,035
		<u>159,355</u>	<u>147,560</u>

For the year ending 31 August 2022 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. No members have required the company to obtain an audit of the financial statements for the year ending 31 August 2022 in accordance with section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for ensuring that the charity keeps accounting records which comply with section 386 of the Act and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its incoming resources and application of resources, including its income and expenditure, for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees on 30/04/2023, and signed on behalf of the board by:



Prof T H Shah -Trustee

## NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2022

### 1. Accounting Policies

#### Accounting convention

The accounts have been prepared in accordance with the Companies Act 2006 and “Accounting and Reporting by Charities: Statement of Recommended Practice (SORP) applicable in the UK and Republic of Ireland (FRS 102)” (as amended for accounting periods commencing from 1 January 2016). The charity is a “Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charity.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

#### Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

#### Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

#### Incoming resources

These are included in the Statement of Financial Activities (SOFA) when:

- The charity becomes legally entitled to the resources after any performance conditions have been met;
- The trustees are virtually certain that they will receive the resources; and
- The monetary value can be measured with sufficient reliability.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount.

Charitable income includes sponsorship of the annual conference and contributions towards the charity's objectives.

## NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2022

### 1. Accounting Policies (continued)

#### Resources expended

Charitable activities includes all costs relating to the conference, newsletters and general administration, which support the charitable purpose.

Grants offered subject to conditions, which have not been met at the year-end date are noted as a commitment, but not accrued as expenditure.

Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Where costs cannot be directly attributed to particular headings that have been allocated to activities on a basis consistent with the use of the resources.

#### Incoming resources with related expenditure

When incoming resources have related expenditure (as with fundraising or contract income) both are reported gross in the SOFA.

#### Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values their useful lives on the following bases:

Computers – straight line over 3 years

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in net income/(expenditure) for the year.

#### Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with bankers, other short term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

#### Financial instruments

The charity has elected to apply the provisions of Section 11 “Basic Financial Instruments” and Section 12 “Other Financial Issues” of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity’s balance sheet when the charity becomes party to the contractual provisions of the instrument.

## NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2022

### 1. Accounting Policies (continued)

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the assets and settle the liability simultaneously.

#### **Basic financial assets**

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price, including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market value of interest. Financial assets classified as receivable within one year are not amortised.

#### **Basic financial liabilities**

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

#### **De-recognition of financial liabilities**

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

### 2. Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

### 3. Donations and legacies

	<b>Unrestricted Funds</b>	<b>Restricted funds</b>	<b>Total</b>	<b>Total</b>
	<b>2022</b>	<b>2022</b>	<b>2022</b>	<b>2021</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
Donations and gifts	-	-	-	-
Membership fees	20,108	-	20,108	17,121
Total for the year	<u>20,108</u>	<u>-</u>	<u>20,108</u>	<u>17,121</u>

# UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2022

### 4. Charitable activities

	Sponsorship	Grants	Total	Total
	2022 £	2022 £	2022 £	2021 £
Sales within charitable activities	77,748	-	77,748	78,045
Performance related grants	-	-	-	-
Total for the year	<u>77,748</u>	<u>-</u>	<u>77,748</u>	<u>78,045</u>

#### Analysis by fund

Unrestricted funds				-
Restricted funds	-	-	-	-
	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>

### 5. Charitable activities

	2022 £	2021 £
Depreciation and impairment	-	-
Conferences and newsletters	31,919	20,484
	<u>31,919</u>	<u>20,484</u>
Share of support costs (note 6)	23,876	29,818
Share of governance costs (note 6)	30,266	24,603
Application developments costs	-	10,800
	<u>86,061</u>	<u>85,705</u>

#### Analysis by fund

Unrestricted funds	86,061	74,905
Restricted funds	-	10,800
	<u>86,061</u>	<u>85,705</u>

NOTES TO THE FINANCIAL STATEMENTS  
YEAR ENDED 31 AUGUST 2022

6. Support costs

	Support costs	Governance costs	Total	Total
	2022 £	2022 £	2022 £	2021 £
ENET membership subscriptions	6,380	-	6,380	12,178
Website	3,946	-	3,946	3,090
Management fees	13,550	-	13,550	14,550
Independent examiner and accountancy fees	-	1,680	1,680	1,440
Other operating costs	-	27,596	27,596	18,620
Committee meetings	-	990	990	4,543
	<u>23,876</u>	<u>30,266</u>	<u>54,142</u>	<u>54,421</u>
Analysed between Charitable activities	<u>23,876</u>	<u>30,266</u>	<u>54,142</u>	<u>54,421</u>

7. Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year (2022 - £nil).

8. Employees

There were no employees during the year. (2022 – nil).

9. Tangible fixed assets

	Computers £
<b>Cost</b> At 1 September 2021 and 31 August 2022	<u>-</u>
<b>Depreciation and impairment</b> At 1 September 2021 and 31 August 2022	<u>-</u>
<b>Carrying amount</b> At 31 August 2022	<u>-</u>
At 31 August 2021 Charitable activities	<u>-</u>

# UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2022

### 10. Financial instruments

	2022 £	2021 £
<b>Carrying amount of financial assets</b>		
Debt instruments measured at amortised cost	-	-
<b>Carrying value of financial liabilities</b>		
Measured on amortised costs	-	-

### 11. Debtors

	2022 £	2021 £
Amount due from Bio	36,318	50,728
Prepayments	13,600	13,599
	<u>49,918</u>	<u>64,327</u>

### 12. Creditors: amounts falling due within one year

	2022 £	2021 £
Deferred income	0	4,732
Other creditors	2,840	0
Accruals and deferred income	3,706	10,800
	<u>6,546</u>	<u>15,532</u>

### 13. Other deferred income

	2022 £	2021 £
Other deferred income	-	4,732

**NOTES TO THE FINANCIAL STATEMENTS  
YEAR ENDED 31 AUGUST 2022**

**14. Restricted funds**

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	<b>Balance at 1 September 2021</b>	<b>Movement in funds</b>		<b>Balance at 31 August 2022</b>
	£	<b>Incoming resources</b>	<b>Resources expended</b>	£
Grants	11,150	-	-	11,150
TransNET	4,925	-	-	4,925
Mobile app development	7,450	-	-	7,450
	<u>23,525</u>	<u>-</u>	<u>-</u>	<u>23,525</u>

**15. Analysis of net assets between funds**

Fund balances at 31 August 2022 and 31 August 2021 are represented by current assets/(liabilities).

**16. Related party transaction**

There were no disclosable related party transactions during the year (2022 – none).

**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY**

England & Wales - Charity number 1148145

---

# Accounts

---

# **UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**

---

## **TRUSTEES REPORT (INCLUDING DIRECTORS REPORT)**

### **YEAR ENDED 31 AUGUST 2021**

The trustees, who are also directors of the charity for the purposes of the Companies Act 2006, present their report and unaudited financial statements of the charity for the year ending 31 August 2021.

#### **Trustees**

The trustees, who are also the directors for the purposes of company law, and who served during the year and up to the date of signature of the unaudited financial statements were:

Prof J Newell-Price

Prof J Ramage

Prof T H Shah

Prof C Thirlwell – appointed 2 December 2019

None of the directors has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £1 in the event of winding up.

The Society has two main categories of membership as follows: Clinician and Consultant Members; Trainee, Nurse, Scientist and Allied Health Professional Members. The latter are given the option of membership with or without inclusive ENETS membership. Membership of the charity is open to any medical professionals or organisations interested in promoting the objects.

#### **Governing document**

The UK and Ireland Neuroendocrine Tumour Society Limited (UKI NETS) is constituted by its Memorandum & Articles of Association, adopted by the membership on 1 December 2014, and is a registered charity. UKI NETS became a company limited by guarantee on 13 August 2008 and was subsequently registered as a charity on 16 July 2012.

#### **Organisational structure**

The Society has two main categories of membership as follows: Clinician and Consultant Members; Trainee, Nurse, Scientist and Allied Health Professional Members. The latter are given the option of membership with or without inclusive ENETS membership. Membership of the charity is open to any medical professionals or organisations interested in promoting the objects.

The Society is governed by four Executive Officers, who are the directors and trustees (Chair, Past Chair, Treasurer and Secretary), supported by a wider Executive Committee, which includes chairs of the sub committees.

#### **Risk management**

The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error.

## **TRUSTEES REPORT (INCLUDING DIRECTORS REPORT)**

**YEAR ENDED 31 AUGUST 2021**

### **Objectives and activities**

The charity's objects are to promote for the public benefit research, education and clinical practice in neuroendocrine tumours by the organisation of conferences, training courses and publications, by raising public awareness, liaison with national and international legislators, and by any other appropriate means. The Society aims to improve the diagnosis and therapy of patients with neuroendocrine tumours within a national multidisciplinary and scientific context.

In furtherance of its objects, the Society shall have the following powers:

1. To arrange and provide for the holding of meetings, lectures and seminars.
2. To procure to be written and print, publish, issue and circulate gratuitously or otherwise such papers, periodicals, pamphlets or other documents.
3. To raise funds and to invite and receive contributions from any person or persons whatsoever by way of subscriptions and otherwise provided that the Society shall not undertake any permanent trading activities in raising funds for its primary charitable objectives.
4. To co-operate, associate or affiliate with any other charitable institutions.
5. To do all such other lawful things as are necessary for the attainment of the above objectives.

The summary of main activities in relation to the charity objectives are as follows:

- Annual Scientific Meeting
- Provision of travel grants
- Provision of meeting awards
- Allocation of research grants
- Provision of educational activities
- Guideline development
- Public engagement

### **Achievements and performance**

#### **UKI NETS 18<sup>th</sup> Annual Conference: Online 2020**

The 18th Annual Conference of the Society was held Online on Monday 30 November 2020. This was the first time that the conference had been held virtually, due to the COVID-19 pandemic. The Society welcomed 208 people to the event, only 21 fewer than the previous years' event which was held in London in 2019.

Sessions ran from early afternoon until early evening, focusing on NET Diagnostic Approaches over the last 20 years from Surgical, Gastroenterology, Endocrinology, Medical Oncology approach and the Patient Perspective. 'Challenging the Experts' sessions reviewed three selected trainee case presentations, focusing on everyday NET challenges and inviting questions and discussion. Oral abstract presentations held on day

4 included topics such as Liver metastases of neuroendocrine neoplasms, Omic Gene Clusters and the challenges presented by COVID-19 to the NCUK care experience. The conference ended with a Prize Giving session.

## **TRUSTEES REPORT (INCLUDING DIRECTORS REPORT)**

### **YEAR ENDED 31 AUGUST 2021**

#### **Provision of travel grants**

As the conference was held online in 2020, no travel grants were awarded.

#### **Provision of meeting awards**

Prizes were awarded to the best scoring clinical and scientific posters and oral communication at the 18<sup>th</sup> Annual Conference.

#### **Provision of Research grants**

UKI NETS and the NET Patient Foundation awarded one research grant of £25k to provide pump-priming funds to support research a project aimed at improving outcomes for patients with Neuroendocrine Tumours.

#### **Public Engagement**

UKI NETS members speak regularly at regional events aimed to help NET patients across the UK in collaboration with the NET Patient Foundation and other organisations.

#### **Educational activities**

UKINETS organised a NETs for Newcomers Training Day (formerly NET Basics Day) that was postponed until May 2021 and held online, due to the COVID-19 pandemic. The aims of this training day were to give participants (including doctors of all specialties) in the management of Neuroendocrine Tumours and:

1. To feel confident to plan outpatient care and initial investigations for a patient with a NET
2. To be able to present the patient to the NET MDT including awareness of terminology
3. To independently manage side effects of carcinoid syndrome and commonly used treatments for NET tumours

UKINETS continues to expand its Library of Bitesize Guidance which is available on the UKINETS website. These are accessible clinical documents relating to specific areas of NET management.

Sessions included a Q&A with a panel of International experts and encouraged lots of interaction.

#### **Dietitians' Working Group**

# UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

---

The chair of the dietitians' working group remained as a co-optee on the Executive Committee.

## **Sponsor Support**

There was financial support to the Society in the form of sponsorship from companies throughout the pharmaceutical industry. The majority of the funding was provided as sponsorship for the National Conference and NETs Basics Training Day. Sponsorship packages were developed by the Treasurer to give companies options for different levels and areas of support moving forwards.

## **TRUSTEES REPORT (INCLUDING DIRECTORS REPORT)**

### **YEAR ENDED 31 AUGUST 2021**

#### **Website**

The charity's website provides an important tool to inform members and the general public about the activities of the Society. <http://www.ukinets.org>.

#### **Communications**

UKI NETS communicates with its members by means of a newsletter containing highlights from previous conferences, information on clinical trials and other Society news. In addition, the charity highlights on its website news stories from the media relating to the field of neuroendocrine tumours. The charity also has its own Twitter account @UKINETS.

#### **PROMNET app**

Along with the NET Patient Foundation, UKINETS continued to be involved in a project to develop a mobile application to empower patients with regards to managing their neuroendocrine tumour. The app gained IRAS approval in 2020 and will act as a tool for patients to track their symptoms, collect data and communicate with the clinical team. The development of the app was funded by Imaging Equipment Ltd.

#### **Clinical Trials**

The NET Clinical Studies Group which monitors and compiles summaries of clinical trials presents updates and reports at the UKINETS Annual Conference. The Research SubCommittee of UKINETS also aims to keep the UKINETS website and NET Patient Foundation up to date with trials that are currently recruiting.

#### **COVID-19**

UKINETS released guidance and statements regarding the evolving COVID-19 pandemic and its impact on NET patients and their HCPs.

#### **Link with the European Neuroendocrine Tumour Society (ENETS)**

UKI NETS continues to provide free membership to its members to its European partner Society, ENETS. Through membership of ENETS, UKI NETS members have access to the

journal *Neuroendocrinology* and a reduced rate for the ENETS annual conference. This inclusive membership is optional for trainees, nurses, scientists and allied health professionals.

## **Financial review**

### **Principal funding sources**

Income to the Society is mainly generated through industry support, the annual conference and membership subscriptions. Personal donations/legacies are received on an ad hoc basis.

### **Reserves policy**

The reserve policy takes into consideration the major risks that could face the Society.

It is the policy of the Society to maintain unrestricted funds, which are the free reserves of the charity. The reserves are held at a level that ensures the financial viability of the Society. That level is deemed to be one that equates to a minimum of one year's expenditure. The balance sheet indicates that there are £124,035 unrestricted funds as at 31 August 2021. This provides sufficient funds to cover management, administration and support costs.

## **TRUSTEES REPORT (INCLUDING DIRECTORS REPORT**

### **YEAR ENDED 31 AUGUST 2021**

#### **Plans for future periods**

The UKI NETS 19th Annual Conference is scheduled to be held virtually in December 2021 due to the coronavirus pandemic. The first day will celebrate the history of UKI NETS and Advances in NET Diagnostic Approach.

Abstracts have been submitted as usual and prizes will be awarded to the highest scoring presentations during the conference.

Other plans for the coming year include:

- Holding a further NETs for Newcomers training event virtually in February 2021 due to its postponement in 2020 – held in May 2021.
- Further developing the library of bite size clinical guidance for the website and reviewing older guidelines
- Developing a Carcinoid Heart Disease Conference postponed from 2020
- Delivery of broader training for nurses, AHPs, GPs, junior doctors and other non-specialists
- Development of a liver transplantation delivery programme and associated service development and research opportunities, in collaboration with LAG, NHFBT and SIGTO.
- Development of additional online content for UKI NETS members
- UKI NETS coordination of European NET studies in the UK
- NET dietetics survey and guidance
- Annual conference plans to be confirmed in accordance with COVID-19
- Providing feedback on external clinical guidelines
- Continuing to secure funding from corporate donors
- Continuing to develop communications with members

## **UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**

---

Working with other societies and foundations to fund and promote NETS knowledge and research

The Trustees Report was approved by the Board of Trustees and signed on its behalf by:

Prof T H Shah

Trustee

Dated:

Charity Registration Number: 1148145

Company Registration Number: 06672185 (England and Wales)

**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**  
**UNAUDITED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 AUGUST 2021**

# UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

---

## CONTENTS

	Page
Legal and administrative information	2
Trustees' Report	3 to 7
Independent examiners report	8
Statement of financial activities	9
Balance sheet	10
Notes to the financial statements	11 to 17

## UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

---

### LEGAL AND ADMINISTRATIVE INFORMATION

#### Trustees

Prof J Newell-Price  
Prof J Ramage  
Prof T H Shah  
Prof C Thirwell

#### Registered Office

138 Digbeth  
Birmingham  
B5 6DR

**Charity number:** 1148145

**Company number:** 06672185 (registered in England and Wales)

#### Independent Examiner

Paul Bowater  
BVSC Accountancy Services  
First Floor  
Livery Place  
35 Livery Street  
Birmingham  
B3 2PB

## UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

---

### TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2021

The trustees, who are also directors of the charity for the purposes of the Companies Act 2006, present their report and unaudited financial statements of the charity for the year ending 31 August 2021.

#### **Trustees**

The trustees, who are also the directors for the purposes of company law, and who served during the year and up to the date of signature of the unaudited financial statements were:

Prof J Newell-Price

Prof J Ramage

Prof T H Shah

Prof C Thirlwell

None of the directors has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £1 in the event of winding up.

The Society has two main categories of membership as follows: Clinician and Consultant Members; Trainee, Nurse, Scientist and Allied Health Professional Members. The latter are given the option of membership with or without inclusive ENETS membership. Membership of the charity is open to any medical professionals or organisations interested in promoting the objects.

#### **Governing document**

The UK and Ireland Neuroendocrine Tumour Society Limited (UKI NETS) is constituted by its Memorandum & Articles of Association, adopted by the membership on 1 December 2014, and is a registered charity. UKI NETS became a company limited by guarantee on 13 August 2008 and was subsequently registered as a charity on 16 July 2012.

#### **Organisational structure**

The Society has two main categories of membership as follows: Clinician and Consultant Members; Trainee, Nurse, Scientist and Allied Health Professional Members. The latter are given the option of membership with or without inclusive ENETS membership. Membership of the charity is open to any medical professionals or organisations interested in promoting the objects.

The Society is governed by four Executive Officers, who are the directors and trustees (Chair, Past Chair, Treasurer and Secretary), supported by a wider Executive Committee, which includes chairs of the sub committees.

#### **Risk management**

The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error.

## UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

---

### TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2021

#### Objectives and activities

The charity's objects are to promote for the public benefit research, education and clinical practice in neuroendocrine tumours by the organisation of conferences, training courses and publications, by raising public awareness, liaison with national and international legislators, and by any other appropriate means. The Society aims to improve the diagnosis and therapy of patients with neuroendocrine tumours within a national multidisciplinary and scientific context.

In furtherance of its objects, the Society shall have the following powers:

1. To arrange and provide for the holding of meetings, lectures and seminars.
2. To procure to be written and print, publish, issue and circulate gratuitously or otherwise such papers, periodicals, pamphlets or other documents.
3. To raise funds and to invite and receive contributions from any person or persons whatsoever by way of subscriptions and otherwise provided that the Society shall not undertake any permanent trading activities in raising funds for its primary charitable objectives.
4. To co-operate, associate or affiliate with any other charitable institutions.
5. To do all such other lawful things as are necessary for the attainment of the above objectives.

The summary of main activities in relation to the charity objectives are as follows:

- Annual Scientific Meeting
- Provision of travel grants
- Provision of meeting awards
- Allocation of research grants
- Provision of educational activities
- Guideline development
- Public engagement

#### Achievements and performance

##### UKI NETS 18<sup>th</sup> Annual Conference: Online 2020

The 18th Annual Conference of the Society was held Online on Monday 30 November 2020. This was the first time that the conference had been held virtually, due to the COVID-19 pandemic. The Society welcomed 208 people to the event, only 21 fewer than the previous years' event which was held in London in 2019.

Sessions ran from early afternoon until early evening, focusing on NET Diagnostic Approaches over the last 20 years from Surgical, Gastroenterology, Endocrinology, Medical Oncology approach and the Patient Perspective. 'Challenging the Experts' sessions reviewed three selected trainee case presentations, focusing on everyday NET challenges and inviting questions and discussion. Oral abstract presentations held on day 4 included topics such as Liver metastases of neuroendocrine neoplasms, Omic Gene Clusters and the challenges presented by COVID-19 to the NCUK care experience. The conference ended with a Prize Giving session.

## UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

---

### TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2021

#### Provision of travel grants

As the conference was held online in 2020, no travel grants were awarded.

#### Provision of meeting awards

Prizes were awarded to the best scoring clinical and scientific posters and oral communication at the 18<sup>th</sup> Annual Conference.

#### Provision of Research grants

UKI NETS and the NET Patient Foundation awarded one research grant of £25k to provide pump-priming funds to support research a project aimed at improving outcomes for patients with Neuroendocrine Tumours.

#### Public Engagement

UKI NETS members speak regularly at regional events aimed to help NET patients across the UK in collaboration with the NET Patient Foundation and other organisations.

#### Educational activities

UKINETS organised a NETs for Newcomers Training Day (formerly NET Basics Day) that was postponed until May 2021 and held online, due to the COVID-19 pandemic. The aims of this training day were to give participants (including doctors of all specialties) in the management of Neuroendocrine Tumours and:

1. To feel confident to plan outpatient care and initial investigations for a patient with a NET
2. To be able to present the patient to the NET MDT including awareness of terminology
3. To independently manage side effects of carcinoid syndrome and commonly used treatments for NET tumours

UKINETS continues to expand its Library of Bitesize Guidance which is available on the UKINETS website. These are accessible clinical documents relating to specific areas of NET management.

Sessions included a Q&A with a panel of International experts and encouraged lots of interaction.

#### Dietitians' Working Group

The chair of the dietitians' working group remained as a co-optee on the Executive Committee.

#### Sponsor Support

There was financial support to the Society in the form of sponsorship from companies throughout the pharmaceutical industry. The majority of the funding was provided as sponsorship for the National Conference and NETs Basics Training Day. Sponsorship packages were developed by the Treasurer to give companies options for different levels and areas of support moving forwards.

## UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

---

### TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2021

#### Website

The charity's website provides an important tool to inform members and the general public about the activities of the Society. <http://www.ukinets.org>.

#### Communications

UKI NETS communicates with its members by means of a newsletter containing highlights from previous conferences, information on clinical trials and other Society news. In addition, the charity highlights on its website news stories from the media relating to the field of neuroendocrine tumours. The charity also has its own Twitter account @UKINETs.

#### PROMNET app

Along with the NET Patient Foundation, UKINETs continued to be involved in a project to develop a mobile application to empower patients with regards to managing their neuroendocrine tumour. The app gained IRAS approval in 2020 and will act as a tool for patients to track their symptoms, collect data and communicate with the clinical team. The development of the app was funded by Imaging Equipment Ltd.

#### Clinical Trials

The NET Clinical Studies Group which monitors and compiles summaries of clinical trials presents updates and reports at the UKINETs Annual Conference. The Research SubCommittee of UKINETs also aims to keep the UKINETs website and NET Patient Foundation up to date with trials that are currently recruiting.

#### COVID-19

UKINETs released guidance and statements regarding the evolving COVID-19 pandemic and its impact on NET patients and their HCPs.

#### Link with the European Neuroendocrine Tumour Society (ENETS)

UKI NETS continues to provide free membership to its members to its European partner Society, ENETS. Through membership of ENETS, UKI NETS members have access to the journal *Neuroendocrinology* and a reduced rate for the ENETS annual conference. This inclusive membership is optional for trainees, nurses, scientists and allied health professionals.

#### Financial review

##### Principal funding sources

Income to the Society is mainly generated through industry support, the annual conference and membership subscriptions. Personal donations/legacies are received on an ad hoc basis.

# UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

## TRUSTEES REPORT (INCLUDING DIRECTORS REPORT YEAR ENDED 31 AUGUST 2021

### Reserves policy

The reserve policy takes into consideration the major risks that could face the Society.

It is the policy of the Society to maintain unrestricted funds, which are the free reserves of the charity. The reserves are held at a level that ensures the financial viability of the Society. That level is deemed to be one that equates to a minimum of one year's expenditure. The balance sheet indicates that there are £124,035 unrestricted funds as at 31 August 2021. This provides sufficient funds to cover management, administration and support costs.

### Plans for future periods

The UKI NETS 19th Annual Conference is scheduled to be held virtually in December 2021 due to the coronavirus pandemic. The first day will celebrate the history of UKI NETS and Advances in NET Diagnostic Approach.

Abstracts have been submitted as usual and prizes will be awarded to the highest scoring presentations during the conference.

Other plans for the coming year include:

- Holding a further NETs for Newcomers training event virtually in February 2021 due to its postponement in 2020 – held in May 2021.
- Further developing the library of bite size clinical guidance for the website and reviewing older guidelines
- Developing a Carcinoid Heart Disease Conference postponed from 2020
- Delivery of broader training for nurses, AHPs, GPs, junior doctors and other non-specialists
- Development of a liver transplantation delivery programme and associated service development and research opportunities, in collaboration with LAG, NHFBT and SIGTO.
- Development of additional online content for UKI NETS members
- UKI NETs coordination of European NET studies in the UK
- NET dietetics survey and guidance
- Annual conference plans to be confirmed in accordance with COVID-19
- Providing feedback on external clinical guidelines
- Continuing to secure funding from corporate donors
- Continuing to develop communications with members


Working with other societies and foundations to fund and promote NETS knowledge and research

The Trustees Report was approved by the Board of Trustees and signed on its behalf by:

Prof T H Shah

Trustee

Dated:

  
11/07/2022

## UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

---

### INDEPENDENT EXAMINERS REPORT TO THE TRUSTEES OF UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

I report to the trustees on my examination of the financial statements of UK and Ireland Neuroendocrine Tumour Society Limited for the year ending 31 August 2021.

#### Responsibilities and basis of report

As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).

Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for an independent examination. I report in respect of the examination of the charity's financial statements carried out under section 144 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

#### Independent Examiner's Statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
2. the financial statements do not accord with those records; or
3. the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).;

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Paul Bowater ACA  
BVSC Accountancy Services  
First Floor  
Livery Place  
35 Livery Street  
Birmingham  
B3 2PB

Dated: 11/07/22

## UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

### STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND EXPENDITURE ACCOUNT)

YEAR ENDED 31 AUGUST 2021

	Note	Unrestricted funds	Restricted funds	Total	Total
		2021	2021	2021	2020
		£	£	£	£
<b><u>Income from:</u></b>					
Donations and legacies	3	17,121	-	17,121	16,544
<b><u>Charitable activities</u></b>					
Sponsorship	4	78,045	-	78,045	117,983
Grants	4	-	-	-	-
<b>Total income</b>		<b>95,166</b>	<b>95,166</b>	<b>95,166</b>	<b>134,527</b>
<b><u>Expenditure on:</u></b>					
<b><u>Charitable activities</u></b>					
Research grant		-	-	-	-
Other charitable expenditure	5	74,905	10,800	85,705	97,691
<b>Total charitable expenditure</b>		<b>74,905</b>	<b>10,800</b>	<b>85,705</b>	<b>97,691</b>
Other resources expended		95	-	95	68
<b>Total resources expended</b>		<b>75,000</b>	<b>10,800</b>	<b>85,800</b>	<b>97,759</b>
<b>Net income for the year/Net movement in funds</b>		<b>20,166</b>	<b>(10,800)</b>	<b>9,366</b>	<b>36,768</b>
<b>Fund balances at 1 September 2020</b>		<b>103,869</b>	<b>34,325</b>	<b>138,194</b>	<b>101,426</b>
<b>Fund balances at 31 August 2021</b>		<b>124,035</b>	<b>23,525</b>	<b>147,560</b>	<b>138,194</b>

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

BALANCE SHEET  
AS AT 31 AUGUST 2021

	Note	2021 £	2020 £
Fixed assets	9	-	-
Current assets			
Debtors	11	64,327	13,599
Cash at bank and in hand		98,765	136,439
		<u>163,092</u>	<u>150,038</u>
Creditors: amounts falling due with one year	12	(15,532)	(11,844)
Net current assets		<u>147,560</u>	<u>138,194</u>
Total assets less current liabilities		<u>147,560</u>	<u>138,194</u>
Income funds			
Restricted funds	14	23,525	34,325
Unrestricted funds		124,035	103,869
		<u>147,560</u>	<u>138,194</u>

For the year ending 31 August 2021 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. No members have required the company to obtain an audit of the financial statements for the year ending 31 August 2021 in accordance with section 476 of the Companies Act 2006.


The trustees acknowledge their responsibilities for ensuring that the charity keeps accounting records which comply with section 386 of the Act and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its incoming resources and application of resources, including its income and expenditure, for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees on \_\_\_\_\_, and signed on behalf of the board by:

Prof T H Shah

Trustee

  
11/07/2022



## UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

---

### NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2021

#### 1. Accounting Policies

##### Accounting convention

The accounts have been prepared in accordance with the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice (SORP) applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016). The charity is a "Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charity.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

##### Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

##### Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

##### Incoming resources

These are included in the Statement of Financial Activities (SOFA) when:

- The charity becomes legally entitled to the resources after any performance conditions have been met;
- The trustees are virtually certain that they will receive the resources; and
- The monetary value can be measured with sufficient reliability.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount.

Charitable income includes sponsorship of the annual conference and contributions towards the charity's objectives.

## UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

---

### NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2021

#### 1. Accounting Policies (continued)

##### **Resources expended**

Charitable activities includes all costs relating to the conference, newsletters and general administration, which support the charitable purpose.

Grants offered subject to conditions, which have not been met at the year-end date are noted as a commitment, but not accrued as expenditure.

Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Where costs cannot be directly attributed to particular headings that have been allocated to activities on a basis consistent with the use of the resources.

##### **Incoming resources with related expenditure**

When incoming resources have related expenditure (as with fundraising or contract income) both are reported gross in the SOFA.

##### **Tangible fixed assets**

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values their useful lives on the following bases:

Computers – straight line over 3 years

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in net income/(expenditure) for the year.

##### **Cash and cash equivalents**

Cash and cash equivalents include cash in hand, deposits held at call with bankers, other short term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

##### **Financial instruments**

The charity has elected to apply the provisions of Section 11 "Basic Financial Instruments" and Section 12 "Other Financial Issues" of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

## UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

### NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2020

#### 1. Accounting Policies (continued)

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the assets and settle the liability simultaneously.

##### *Basic financial assets*

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price, including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market value of interest. Financial assets classified as receivable within one year are not amortised.

##### *Basic financial liabilities*

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

##### *De-recognition of financial liabilities*

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

#### 2. Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

#### 3. Donations and legacies

	Unrestricted Funds	Restricted funds	Total	Total
	2021 £	2021 £	2021 £	2020 £
Donations and gifts	-	-	-	2,188
Membership fees	17,121	-	17,121	14,359
Total for the year	<u>17,121</u>	<u>-</u>	<u>17,121</u>	<u>16,544</u>

UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

NOTES TO THE FINANCIAL STATEMENTS  
YEAR ENDED 31 AUGUST 2021

4. Charitable activities

	Sponsorship	Grants	Total	Total
	2021 £	2021 £	2021 £	2020 £
Sales within charitable activities	78,045	-	78,045	117,983
Performance related grants	-	-	-	-
Total for the year	<u>78,045</u>	<u>-</u>	<u>78,045</u>	<u>117,983</u>

Analysis by fund

Unrestricted funds				117,983
Restricted funds	-	-	-	-
	<u>-</u>	<u>-</u>	<u>-</u>	<u>117,983</u>

5. Charitable activities

	2021 £	2020 £
Depreciation and impairment	-	-
Conferences and newsletters	20,484	42,720
	<u>20,484</u>	<u>42,720</u>
Share of support costs (note 6)	29,818	27,602
Share of governance costs (note 6)	24,603	20,169
Application developments costs	10,800	7,200
	<u>85,705</u>	<u>97,691</u>

Analysis by fund

Unrestricted funds	74,905	87,638
Restricted funds	10,800	10,053
	<u>85,705</u>	<u>97,691</u>

## UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

### NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2021

#### 6. Support costs

	Support costs	Governance costs	Total	Total
	2021	2021	2021	2020
	£	£	£	£
ENET membership subscriptions	12,178	-	12,178	7,723
Website	3,090	-	3,090	3,679
Management fees	14,550	-	14,550	16,200
Independent examiner and accountancy fees	-	1,440	1,440	1,440
Other operating costs	-	18,620	18,620	18,260
Committee meetings	-	4,543	4,543	469
	<u>29,818</u>	<u>24,603</u>	<u>54,421</u>	<u>47,771</u>
Analysed between Charitable activities	<u>29,818</u>	<u>24,603</u>	<u>54,421</u>	<u>47,771</u>

#### 7. Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year (2020 - £nil).

#### 8. Employees

There were no employees during the year. (2020 – nil).

#### 9. Tangible fixed assets

	Computers
	£
<b>Cost</b>	
At 1 September 2020 and 31 August 2021	<u>10,420</u>
<b>Depreciation and impairment</b>	
At 1 September 2020 and 31 August 2021	<u>10,420</u>
<b>Carrying amount</b>	
At 31 August 2021	<u>-</u>
At 31 August 2020	<u>-</u>
Charitable activities	<u>-</u>

## UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

### NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2021

#### 10. Financial instruments

	2021 £	2020 £
<b>Carrying amount of financial assets</b>		
Debt instruments measured at amortised cost	<u>-</u>	<u>-</u>
<b>Carrying value of financial liabilities</b>		
Measured on amortised costs	<u>-</u>	<u>-</u>

#### 11. Debtors

	2021 £	2020 £
<b>Amounts falling due within one year</b>		
Other debtors	10,000	10,000
Prepayments and accrued income	54,327	3,599
	<u>64,327</u>	<u>13,599</u>

#### 12. Creditors: amounts falling due within one year

	2021 £	2020 £
Deferred income	4,732	2,312
Accruals	10,800	9,532
	<u>15,532</u>	<u>11,844</u>

#### 13. Other deferred income

	2021 £	2020 £
Other deferred income	<u>4,732</u>	<u>2,312</u>

## UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

### NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2021

#### 14. Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Balance at 1 September 2020	Movement in funds	Resources expended	Balance at 31 August 2021
	£	Incoming resources £	£	£
Grants	11,150	-	-	11,150
TransNET	4,925	-	-	4,925
Mobile app development	18,250	-	10,800	7,450
	<u>34,325</u>	<u>-</u>	<u>10,800</u>	<u>23,525</u>

#### 15. Analysis of net assets between funds

Fund balances at 31 August 2021 and 31 August 2020 are represented by current assets/(liabilities).

#### 16. Related party transaction

There were no disclosable related party transactions during the year (2020 – none).

## **INDEPENDENT EXAMINERS REPORT TO THE TRUSTEES OF UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**

I report to the trustees on my examination of the financial statements of UK and Ireland Neuroendocrine Tumour Society Limited for the year ending 31 August 2021.

### **Responsibilities and basis of report**

As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).


Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for an independent examination. I report in respect of the examination of the charity's financial statements carried out under section 144 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

### **Independent Examiner's Statement**

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
2. the financial statements do not accord with those records; or
3. the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).;

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Paul Bowater ACA  
BVSC Accountancy Services  
First Floor  
Livery Place  
35 Livery Street  
Birmingham  
B3 2PB

Dated: 11 July 2022

**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY**

England & Wales - Charity number 1148145

---

# Accounts

---

**Charity Registration Number: 1148145**

**Company Registration Number: 06672185 (England and Wales)**

**UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**

**UNAUDITED FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED 31 AUGUST 2020**

## CONTENTS

	<b>Page</b>
Legal and administrative information	2
Trustees' Report	3 to 7
Independent examiners report	8
Statement of financial activities	9
Balance sheet	10
Notes to the financial statements	11 to 17

**LEGAL AND ADMINISTRATIVE INFORMATION**

**Trustees**

Prof J Newell-Price

Prof J Ramage

Prof T H Shah

Prof C Thirwell – appointed 2 December 2019

Prof J W Valle – resigned 2 December 2019

**Registered Office**

Athenia House

10-14 Andover Road

Winchester

Hampshire

SO23 7BS

**Charity number:** 1148145

**Company number:** 06672185 (registered in England and Wales)

**Independent Examiner**

BVSC

138 Digbeth

Birmingham

B5 6DR

## **TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2020**

The trustees, who are also directors of the charity for the purposes of the Companies Act 2006, present their report and unaudited financial statements of the charity for the year ending 31 August 2020.

### **Trustees**

The trustees, who are also the directors for the purposes of company law, and who served during the year and up to the date of signature of the unaudited financial statements were:

Prof J Newell-Price

Prof J Ramage

Prof T H Shah

Prof C Thirlwell – appointed 2 December 2019

Prof J W Valle – resigned 2 December 2019

None of the directors has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £1 in the event of winding up.

The Society has two main categories of membership as follows: Clinician and Consultant Members; Trainee, Nurse, Scientist and Allied Health Professional Members. The latter are given the option of membership with or without inclusive ENETS membership. Membership of the charity is open to any medical professionals or organisations interested in promoting the objects.

### **Governing document**

The UK and Ireland Neuroendocrine Tumour Society Limited (UKI NETS) is constituted by its Memorandum & Articles of Association, adopted by the membership on 1 December 2014, and is a registered charity. UKI NETS became a company limited by guarantee on 13 August 2008 and was subsequently registered as a charity on 16 July 2012.

### **Organisational structure**

The Society has two main categories of membership as follows: Clinician and Consultant Members; Trainee, Nurse, Scientist and Allied Health Professional Members. The latter are given the option of membership with or without inclusive ENETS membership. Membership of the charity is open to any medical professionals or organisations interested in promoting the objects.

The Society is governed by four Executive Officers, who are the directors and trustees (Chair, Past Chair, Treasurer and Secretary), supported by a wider Executive Committee, which includes chairs of the sub committees.

### **Risk management**

The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error.

## TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2020

### Objectives and activities

The charity's objects are to promote for the public benefit research, education and clinical practice in neuroendocrine tumours by the organisation of conferences, training courses and publications, by raising public awareness, liaison with national and international legislators, and by any other appropriate means. The Society aims to improve the diagnosis and therapy of patients with neuroendocrine tumours within a national multidisciplinary and scientific context.

In furtherance of its objects, the Society shall have the following powers:

1. To arrange and provide for the holding of meetings, lectures and seminars.
2. To procure to be written and print, publish, issue and circulate gratuitously or otherwise such papers, periodicals, pamphlets or other documents.
3. To raise funds and to invite and receive contributions from any person or persons whatsoever by way of subscriptions and otherwise provided that the Society shall not undertake any permanent trading activities in raising funds for its primary charitable objectives.
4. To co-operate, associate or affiliate with any other charitable institutions.
5. To do all such other lawful things as are necessary for the attainment of the above objectives.

The summary of main activities in relation to the charity objectives are as follows:

- Annual Scientific Meeting
- Provision of travel grants
- Provision of meeting awards
- Allocation of research grants
- Provision of educational activities
- Guideline development
- Public engagement

### Achievements and performance

#### UKI NETS 17<sup>th</sup> Annual Conference: Birmingham, December 2019

The 17th Annual Conference of the Society was held on 2 December 2019 at the MacDonald Burlington Hotel in Birmingham. This was the third time that the conference had been held outside London and the Society welcomed 229 people to the event, with the biggest number of delegates seen at a UKI NETS conference. The morning sessions focused on Daily Clinical dilemmas in NEN & NEN disease from patients' perspective and Optimal surgical approach for GEP-NEN in 2019. A Challenging the Experts session in the afternoon gave the opportunity for delegates to quiz a range of experts, including a gastroenterologist, endocrinologist, oncologist, surgeon, histopathologist, radiologist, nuclear medicine physician and nurse specialist. Following this was a session on translational science where the international guest speaker, Prof Eric Raymond from France, gave an insight into Translational science in NETS opportunities and pitfalls, while previous UKINETS Research Grant winners gave updates on their projects and the grant for 2019 was awarded. Also in the afternoon, the 3 selected oral presentations all addressed important topics. The final session focused on Liver Transplantation for NEN. The day ended with a Clinical Trials Update and a Prize Giving session.

## TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2020

### Provision of travel grants

The 10 highest scoring abstracts submitted to the 17<sup>th</sup> Annual Conference were awarded travel grants to attend the conference. Non-members were awarded this grant in the form of complimentary membership for the next membership year.

### Provision of meeting awards

Prizes were awarded to the best scoring clinical and scientific posters and oral communication at the 17<sup>th</sup> Annual Conference.

### Provision of Research grants

UKI NETS and the NET Patient Foundation awarded one research grant of £25k to provide pump-priming funds to support research a project aimed at improving outcomes for patients with Neuroendocrine Tumours.

### Public Engagement

UKI NETS members speak regularly at regional events aimed to help NET patients across the UK in collaboration with the NET Patient Foundation and other organisations.

### Educational activities

UKINETS organised a NETs for Newcomers Training Day (formerly NET Basics Day) in September 2019, in London, with 55 attendees. The aims of this training day were to give participants (including trainees and consultants who may have little or no experience of NETs) an introduction to NET medicine and:

1. To feel confident to plan outpatient care and initial investigations for a patient with a NET
2. To be able to present the patient to the NET MDT including awareness of terminology
3. To independently manage side effects of carcinoid syndrome and commonly used treatments for NET tumours

UKINETS continues to expand its Library of Bitesize Guidance which is available on the UKINETS website. These are accessible clinical documents relating to specific areas of NET management.

### Dietitians' Working Group

The chair of the dietitians' working group remained as a co-optee on the Executive Committee.

### Sponsor Support

There was financial support to the Society in the form of sponsorship from companies throughout the pharmaceutical industry. The majority of the funding was provided as sponsorship for the National Conference and NETs Basics Training Day. Sponsorship packages were developed by the Treasurer to give companies options for different levels and areas of support moving forwards.

## TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2020

### Website

The charity's website provides an important tool to inform members and the general public about the activities of the Society. <http://www.ukinets.org>.

### Communications

UKI NETS communicates with its members by means of a newsletter containing highlights from previous conferences, information on clinical trials and other Society news. In addition, the charity highlights on its website news stories from the media relating to the field of neuroendocrine tumours. The charity also has its own Twitter account @UKINETS.

### PROMNET app

Along with the NET Patient Foundation, UKINETS continued to be involved in a project to develop a mobile application to empower patients with regards to managing their neuroendocrine tumour. The app gained IRAS approval in 2020 and will act as a tool for patients to track their symptoms, collect data and communicate with the clinical team. The development of the app was funded by Imaging Equipment Ltd.

### Clinical Trials

The NET Clinical Studies Group which monitors and compiles summaries of clinical trials presents updates and reports at the UKINETS Annual Conference. The Research Sub-Committee of UKINETS also aims to keep the UKINETS website and NET Patient Foundation up to date with trials that are currently recruiting.

UKI NETS worked with the Liver Advisory Group to secure approval of a pilot study for liver transplantation in NET liver metastases. This is a major new development in management of NETs and will provide significant research opportunities. The pilot programme will be overseen by UKINETS in collaboration with and participation by the UK and Ireland ENET Centres of Excellence as well as Liver Advisory Group and Specialist Interest Group for Transplant Oncology. UKINETS will need to provide leadership and logistics through a national delivery board.

### COVID-19

UKINETS released guidance and statements regarding the evolving COVID-19 pandemic and its impact on NET patients and their HCPs.

### Link with the European Neuroendocrine Tumour Society (ENETS)

UKI NETS continues to provide free membership to its members to its European partner Society, ENETS. Through membership of ENETS, UKI NETS members have access to the journal *Neuroendocrinology* and a reduced rate for the ENETS annual conference. This inclusive membership is optional for trainees, nurses, scientists and allied health professionals.

### Financial review

#### Principal funding sources

Income to the Society is mainly generated through industry support, the annual conference and membership subscriptions. Personal donations/legacies are received on an ad hoc basis.

## TRUSTEES REPORT (INCLUDING DIRECTORS REPORT YEAR ENDED 31 AUGUST 2020

### Reserves policy

The reserve policy takes into consideration the major risks that could face the Society.

It is the policy of the Society to maintain unrestricted funds, which are the free reserves of the charity. The reserves are held at a level that ensures the financial viability of the Society. That level is deemed to be one that equates to a minimum of one year's expenditure. The balance sheet indicates that there are £110,711 unrestricted funds as at 31 August 2020. This provides sufficient funds to cover management, administration and support costs.

### Plans for future periods

The UKI NETS 18th Annual Conference is scheduled to be held virtually in December 2020 due to the coronavirus pandemic, with content being released over four days. The first day will celebrate 20 years of UKI NETS and Advances in NET Diagnostic Approach.

Abstracts have been submitted as usual and prizes will be awarded to the highest scoring presentations during the conference.

Other plans for the coming year include:

- Holding a further NETs for Newcomers training event virtually in February 2021 due to its postponement in 2020
- Further developing the library of bite size clinical guidance for the website and reviewing older guidelines
- Developing a Carcinoid Heart Disease Conference postponed from 2020
- Delivery of broader training for nurses, AHPs, GPs, junior doctors and other non-specialists
- Development of a liver transplantation delivery programme and associated service development and research opportunities, in collaboration with LAG, NHFBT and SIGTO.
- Development of additional online content for UKI NETS members
- UKI NETs coordination of European NET studies in the UK
- NET dietetics survey and guidance
- Annual conference plans to be confirmed in accordance with COVID-19
- Providing feedback on external clinical guidelines
- Continuing to secure funding from corporate donors
- Continuing to develop communications with members

Working with other societies and foundations to fund and promote NETS knowledge and research

The Trustees Report was approved by the Board of Trustees and signed on its behalf by:

Prof T H Shah

Dated:

## **INDEPENDENT EXAMINERS REPORT TO THE TRUSTEES OF UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED**

I report to the trustees on my examination of the financial statements of UK and Ireland Neuroendocrine Tumour Society Limited for the year ending 31 August 2020.

### **Responsibilities and basis of report**

As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).

Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for an independent examination. I report in respect of the examination of the charity's financial statements carried out under section 144 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

### **Independent Examiner's Statement**

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
2. the financial statements do not accord with those records; or
3. the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).;

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Paul Bowater ACA  
Birmingham Voluntary Service Council  
138 Digbeth  
Birmingham  
B5 6DR

Dated:

# UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

## STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND EXPENDITURE ACCOUNT) YEAR ENDED 31 AUGUST 2020

	Note	Unrestricted funds	Restricted funds	Total	Total
		2020	2020	2020	2019
		£	£	£	£
<b><u>Income from:</u></b>					
Donations and legacies	3	16,544	-	16,544	43,664
<b><u>Charitable activities</u></b>					
Sponsorship	4	117,983	-	117,983	78,620
Grants	4	-	-	-	-
<b>Total income</b>		<b>134,527</b>	<b>-</b>	<b>134,527</b>	<b>122,284</b>
<b><u>Expenditure on:</u></b>					
<b><u>Charitable activities</u></b>					
Research grant		-	-	-	25,000
Other charitable expenditure	5	87,638	10,053	97,691	120,716
<b>Total charitable expenditure</b>		<b>87,638</b>	<b>10,053</b>	<b>97,691</b>	<b>145,716</b>
Other resources expended		68	-	68	62
<b>Total resources expended</b>		<b>87,706</b>	<b>10,053</b>	<b>97,759</b>	<b>145,778</b>
<b>Net income for the year/Net movement in funds</b>		<b>46,821</b>	<b>(10,053)</b>	<b>36,768</b>	<b>(23,494)</b>
<b>Fund balances at 1 September 2019</b>		<b>57,048</b>	<b>44,378</b>	<b>101,426</b>	<b>124,920</b>
<b>Fund balances at 31 August 2020</b>		<b>103,869</b>	<b>34,325</b>	<b>138,194</b>	<b>101,426</b>

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

# UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

## BALANCE SHEET AS AT 31 AUGUST 2020

	Note	2020 £	2019 £
<b>Fixed assets</b>	9	-	-
<b>Current assets</b>			
Debtors	11	13,599	30,416
Cash at bank and in hand		<u>136,439</u>	<u>86,537</u>
		150,038	116,953
<b>Creditors: amounts falling due with one year</b>	12	(11,844)	(15,527)
<b>Net current assets</b>		<u>138,194</u>	<u>101,426</u>
<b>Total assets less current liabilities</b>		<u>138,194</u>	<u>101,426</u>
<b>Income funds</b>			
Restricted funds	14	34,325	44,378
Unrestricted funds		103,869	57,048
		<u>138,194</u>	<u>101,426</u>

For the year ending 31 August 2020 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. No members have required the company to obtain an audit of the financial statements for the year ending 31 August 2020 in accordance with section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for complying of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees on \_\_\_\_\_, and signed on behalf of the board by:

Prof T H Shah

Trustee

## NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2020

### 1. Accounting Policies

#### Accounting convention

The accounts have been prepared in accordance with the Companies Act 2006 and “Accounting and Reporting by Charities: Statement of Recommended Practice (SORP) applicable in the UK and Republic of Ireland (FRS 102)” (as amended for accounting periods commencing from 1 January 2016). The charity is a “Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charity.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

#### Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis in preparing the financial statements.

#### Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

#### Incoming resources

These are included in the Statement of Financial Activities (SOFA) when:

- The charity becomes legally entitled to the resources after any performance conditions have been met;
- The trustees are virtually certain that they will receive the resources; and
- The monetary value can be measured with sufficient reliability.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount.

Charitable income includes sponsorship of the annual conference and contributions towards the charity’s objectives.

## NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2020

### 1. Accounting Policies (continued)

#### **Resources expended**

Charitable activities includes all costs relating to the conference, newsletters and general administration, which support the charitable purpose.

Grants offered subject to conditions, which have not been met at the year-end date are noted as a commitment, but not accrued as expenditure.

Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Where costs cannot be directly attributed to particular headings that have been allocated to activities on a basis consistent with the use of the resources.

#### **Incoming resources with related expenditure**

When incoming resources have related expenditure (as with fundraising or contract income) both are reported gross in the SOFA.

#### **Tangible fixed assets**

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values their useful lives on the following bases:

Computers – straight line over 3 years

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in net income/(expenditure) for the year.

#### **Cash and cash equivalents**

Cash and cash equivalents include cash in hand, deposits held at call with bankers, other short term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

#### **Financial instruments**

The charity has elected to apply the provisions of Section 11 “Basic Financial Instruments” and Section 12 “Other Financial Issues” of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity’s balance sheet when the charity becomes party to the contractual provisions of the instrument.

NOTES TO THE FINANCIAL STATEMENTS  
YEAR ENDED 31 AUGUST 2020

1. Accounting Policies (continued)

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the assets and settle the liability simultaneously.

**Basic financial assets**

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price, including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market value of interest. Financial assets classified as receivable within one year are not amortised.

**Basic financial liabilities**

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

**De-recognition of financial liabilities**

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

2. Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3. Donations and legacies

	Unrestricted Funds	Restricted funds	Total	Total
	2020 £	2020 £	2020 £	2019 £
Donations and gifts	2,188	-	2,188	31,112
Membership fees	14,356	-	14,356	12,552
Total for the year	16,544	-	16,544	43,664

# UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2020

### 4. Charitable activities

	Sponsorship	Grants	Total	Total
	2020 £	2020 £	2020 £	2019 £
Sales within charitable activities	117,983	-	117,983	78,620
Performance related grants	-	-	-	-
Total for the year	<u>117,983</u>	<u>-</u>	<u>117,983</u>	<u>78,620</u>

#### Analysis by fund

Unrestricted funds	117,983	-	117,983	78,620
Restricted funds	-	-	-	-
	<u>117,983</u>	<u>-</u>	<u>117,983</u>	<u>78,620</u>

### 5. Charitable activities

	2020 £	2019 £
Depreciation and impairment	-	-
Conferences and newsletters	42,720	54,144
	<u>42,720</u>	<u>54,144</u>
Share of support costs (note 6)	27,602	19,188
Share of governance costs (note 6)	20,169	22,834
Application developments costs	7,200	24,550
	<u>97,691</u>	<u>120,716</u>

#### Analysis by fund

Unrestricted funds	87,638	92,016
Restricted funds	10,053	28,700
	<u>97,691</u>	<u>120,716</u>

# UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2020

### 6. Support costs

	Support costs	Governance costs	Total	Total
	2020 £	2020 £	2020 £	2019 £
ENET membership subscriptions	7,723	-	7,723	320
Website	3,679	-	3,679	5,405
Management fees	16,200	-	16,200	13,463
Independent examiner and accountancy fees	-	1,440	1,440	2,185
Other operating costs	-	18,260	18,260	18,741
Committee meetings	-	469	469	1,908
	<u>27,602</u>	<u>20,169</u>	<u>47,771</u>	<u>42,022</u>
Analysed between Charitable activities	<u>27,602</u>	<u>20,169</u>	<u>47,771</u>	<u>42,022</u>

### 7. Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year (2019 - £nil).

### 8. Employees

There were no employees during the year. (2019 – nil).

### 9. Tangible fixed assets

	Computers £
<b>Cost</b>	
At 1 September 2019 and 31 August 2020	<u>10,420</u>
<b>Depreciation and impairment</b>	
At 1 September 2019 and 31 August 2020	<u>10,420</u>
<b>Carrying amount</b>	
At 31 August 2020	<u>-</u>
At 31 August 2019 Charitable activities	<u>-</u>

# UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

## NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2020

### 10. Financial instruments

	2020 £	2019 £
<b>Carrying amount of financial assets</b>		
Debt instruments measured at amortised cost	<u>-</u>	<u>-</u>
<b>Carrying value of financial liabilities</b>		
Measured on amortised costs	<u>-</u>	<u>-</u>

### 11. Debtors

	2020 £	2019 £
<b>Amounts falling due within one year</b>		
Other debtors	10,000	30,417
Prepayments and accrued income	3,599	-
	<u>13,599</u>	<u>30,417</u>

### 12. Creditors: amounts falling due within one year

	2020 £	2019 £
Deferred income	2,312	2,312
Accruals	9,532	13,215
	<u>11,844</u>	<u>15,527</u>

### 13. Other deferred income

	2020 £	2019 £
Other deferred income	<u>2,312</u>	<u>2,312</u>

**NOTES TO THE FINANCIAL STATEMENTS  
YEAR ENDED 31 AUGUST 2020**

**14. Restricted funds**

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	<b>Balance at 1 September 2019</b>	<b>Movement in funds</b>		<b>Balance at 31 August 2020</b>
	£	Incoming resources £	Resources expended £	£
Grants	14,003	-	(2,853)	11,150
TransNET	4,925	-	-	4,925
Mobile app development	25,450	-	(7,200)	18,250
	<u>44,378</u>	<u>-</u>	<u>(10,053)</u>	<u>34,325</u>

**15. Analysis of net assets between funds**

Fund balances at 31 August 2020 and 31 August 2019 are represented by current assets/(liabilities).

**16. Related party transaction**

There were no disclosable related party transactions during the year (2019 – none).